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ABSTRACT 
 
Breast cancer is the most commonly diagnosed cancer among American women. 
G-protein coupled receptors (GPCR) comprise a huge family protein with almost 800 
members. GPCRs sense molecules or other stimuli outside the cell, and activate 
intracellular signals. Consequently, a large proportion of modern drugs target these 
receptors.  Lgr4 is a GPCR implicated in the development of multiple organs; in the 
mammary gland, it is expressed in the basal epithelial subpopulation and controls organ 
development by regulating stem cell activity through the wnt/β-catenin pathway. High 
breast tumor expression of Lgr4 correlated with a high risk of tumor relapse after 
chemokine therapy and an elevated risk of bone metastasis. We crossed mice bearing a 
gene trap cassette in the Lgr4 locus with several breast cancer mouse models such as 
MMTV-Wnt1 and MMTV-PyMT to study the consequences of Lgr4 expression ablation 
in breast cancer progression. We found that the absence of Lgr4 significantly delayed 
tumor progression in both MMTV-Wnt1 and MMTV-PyMT mouse models. Meanwhile, 
Lgr4 ablation led to diminished lung metastases in MMTV-PyMT tumors and several 
breast cancer cell lines. Further studies revealed that the repression of tumor progression 
and metastasis formation was due to a decreased cancer stem cell number in tumors with 
Lgr4 downregulation, as well as blocking of epithelial-mesenchymal transition. 
Mechanistic studies suggested that Lgr4 is a master regulator which modulates multiple 
pathways (Wnt, EGFR, MMP) in breast cancer. Our findings clarify the role of Lgr4 in 
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tumor progression and metastasis formation, and provide a potential therapeutic target in 
breast cancer treatment. 
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NOMENCLATURE 
 
ADP Adenosine diphosphate  
APC Adenomatosis polyposis coli  
AJCC The American Joint Committee on Cancer 
ASD Anterior segment dysgenesis 
BMP Bone Morphogenic Protein 
cAMP Cyclic adenosine monophosphate  
CK1α Casein kinase 1α  
CREB cAMP response element-binding protein 
CSC Cancer stem cell 
DAG Diacyl-glycerol  
Dvl Dishevelled 
ECD Extracellular domain  
ECL Extracellular loops 
EGFR Epidermal Growth Factor Receptor 
EMT Epithelial-Mesenchymal transition 
ER Endoplasmic reticulum  
ER' Estrogen receptor  
FBS Fetal Bovine Serum 
FGF Fibroblast Growth Factor 
FGFR Fibroblast Growth Factor Receptor 
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FSHR Follicle-stimulating hormone receptor  
Fzd Frizzled 
GDP Guanosine diphosphate  
GEF Guanine nucleotide exchange factors  
GI Gastrointestinal 
GPCR G protein-coupled receptor 
GRK G protein-coupled receptor kinase 
GSK3 Glycogen synthase kinase 3  
GTP Guanosine triphosphate  
IL Intracellular loops 
IP3 Inositol 1, 4, 5-trisphosphate  
ISNL Insulin-like  
LEF Lymphoid enhancer binding factor  
LGR Leucine-rich repeats G-protein coupled receptor 
LHR Luteinizing hormone receptor 
LRP Lipoprotein receptor-related protein 
LRR Leucine-rich repeats  
MMTV Mouse mammary tumor virus  
PCP Planar cell polarity  
PIP2 Phosphatidylinositol 4, 5-bisphosphate  
PKA Protein kinase A  
PKC Protein kinase C  
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PLAP Placental alkaline phosphatase 
PLC Phospholipase C  
PP2A Protein phosphatase 2A 
PPi Pyrophosphate 
PR progesterone receptor 
PT Pertussis toxin  
PyMT Polyoma virus-middle T antigen Antibody  
RLXN Relaxins  
RNF43 Ring finger protein 43  
RSPO R-spondin 
RXFP Relaxin and insulin-like family peptide 
TCF T cell factor  
TF Transcriptional factors 
TGF Transforming growth factor (TGF 
TIC Tumor initiating cell 
TM Transmembrane 
TNBC Triple negative breast cancer 
TSHR Thyrotropin receptor  
TSP-1 Thrombospondin 
Wnt  Wingless and Int 
ZEB E-box–binding homeobox  
ZNRF3 Zinc and ring finger 3  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
I.1 GPCR 
I.1.1 Basic classification and structure of GPCRs 
G protein coupled receptors (GPCRs) represent the largest family of 
transmembrane proteins which respond to a remarkable diversity of extracellular ligands 
or mechanical stimuli (Iismaa & Shine, 1992). GPCRs share similar structural traits such 
as an N-terminal extracellular domain, three extracellular loops (ECL1-3), 7 
hydrophobic transmembrane (TM) helical structures, three intracellular loops (IL1-3) 
and a C-terminal intracellular domain (Kobilka, 2007). GPCRs can be divided into 5 
different families based on their phylogenetic sequence characteristics: Rhodopsin-like 
receptors, Glutamate-like receptors, Adhesion-like receptors, Frizzled/tas2 family 
receptors and Secretin-like receptors (Fredriksson, Lagerstrom, Lundin, & Schioth, 
2003). Rhodopsin-like receptors, also called family 1 or class A, consist of the largest 
subgroup of receptors which mainly respond to extracellular hormones, 
neurotransmitters and light, smell and taste stimuli. Almost all rhodopsin-like receptors 
have an Asp-Arg-Tyr (DRY) motif at the cytoplasmic end of the 3rd TM (Schertler, 
2005). Family 1 receptors can be further categorized into Endogenous-ligand and 
Olfactory or Pheromone-ligand receptors based on the nature of their ligands. 
Alternatively, family 1 can also be divided into 19 subgroups (A1-A19) (Joost & 
Methner, 2002; Katritch, Cherezov, & Stevens, 2012) based on maximum likelihood-
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based phylogenetic analysis, a method to study inference of phylogeny (Day & Sankoff, 
1987). Rhodopsin-like receptors have long been used as models for GPCR function and 
structural studies for their diversity. LGR4 (also known as GPR48) falls into this 
category as well. Thus, most of this introduction will focus on Rhodopsin-like receptors.  
Although the universal role of the N-terminal domain in GPCRs is not fully 
understood, some studies show that the N-terminus has a role facilitating ligand binding 
and receptor activation in family 1 and family 2 receptors. For example, the N-terminus 
guides ligand binding and inhibits the endocytosis rate of the dopamine D2 receptor (D. 
I. Cho et al., 2012), and modulates agonist binding affinity and Gαq activity of the 5-
HT2B Receptor (Belmer et al., 2014).  The 7TMs are highly conserved based on 
sequence analysis, and most conformational changes also take place within these 
segments after agonist-induced activation of GPCRs (Katritch et al., 2012).  TM1 and 
TM2 are relatively stable even during receptor activation, possibly because they function 
as location elements which regulate membrane insertion (Kobilka & Deupi, 2007). There 
are strong contacts between TM1 and TM7 which maintain the integrity of the TM 
segments. TM3, TM5, TM6, and TM7 together with ECL2 and ECL3 are the main 
determinants of ligand binding affinity. Unlike the TM segments, the C-terminal, N-
terminal and intracellular loop have the most variable structures which contribute largely 
to the versatility of GPCRs. IL2 and IL3 have been shown to determine the type of Gα 
proteins which certain GPCRs specifically couple. The C terminal domain usually 
contains a high frequency of serine (Ser) or threonine (Thr) residues which will recruit 
arrestins and shut down GPCR signaling after being phosphorylated (Strader, Fong, 
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Tota, Underwood, & Dixon, 1994; Wess, 1998). Despite some rare cases in which small 
agonists bind to the N-terminal domain, most ligands bind within the cavities between 
TM segments to activate GPCRs (Baldwin, 1994). Together, the complexity of both 
GPCR structural transformation and upstream-to-downstream signaling are determined. 
At present,  the major obstacles in GPCR studies are to predict the activities of certain 
GPCRs and to determine their structure through crystallization (Lagerstrom & Schioth, 
2008). 
 
I.1.2 GPCR activation and deactivation  
GPCRs interact reversibly and specifically with different G proteins at their 
cytoplasmic end. There are three subunits of heterotrimeric G proteins: Gα, Gβ and Gγ. 
Usually the G alpha subunit stays monomeric, while Gβ and Gγ form a dimeric complex 
known as the beta-gamma complex when GPCRs are inactive (Seifert, Wenzel-Seifert, 
& Kobilka, 1999). Upon ligand binding, or in response to sensory signals, GPCRs 
undergo conformational changes at the cytoplasmic interface involving IL1, 2, 3 and the 
whole C terminal domain (Kobilka, 2007). Recent studies reveal that most GPCRs have 
relatively conserved conformational changes upon ligand binding, in terms of the non-
covalent contacts between TM and TM and/or ligand to TM (Ghanouni, Steenhuis, 
Farrens, & Kobilka, 2001; Unal & Karnik, 2012). These conformational changes in turn 
recruit Guanine nucleotide exchange factors (GEFs) to activate G proteins. GEFs 
catalyze transition to an active form by releasing guanosine diphosphate (GDP) from the 
Gα subunit and allowing the binding of guanosine triphosphate (GTP) instead. This 
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results in a short-lived dissociation of monomeric Gα-GTP from the Gβγ complex (Vetter 
& Wittinghofer, 2001). The separation between G proteins enables both disseminated 
components to regulate specific biological activities by interacting with downstream 
signaling pathways or cellular effectors. Although most GPCRs are able to function as 
signal transmitters monomerically on the cell membrane, some fascinating data also 
show that GPCRs can form homodimers or heterodimers to activate different signaling 
pathways (Angers, Salahpour, & Bouvier, 2002; Damian, Martin, Mesnier, Pin, & 
Baneres, 2006; Terrillon & Bouvier, 2004). The fact that GPCRs form dimers further 
increases the diversity and complexity of GPCR function and structure. 
In order to turn off activated GPCR signaling, the most well studied mechanism 
is the binding of arrestins to phosphorylated GPCRs in order to block the activation of G 
proteins. In this mechanism, G protein-coupled receptor kinases (GRKs) are recruited 
and phosphorylate serine and threonine residues in IL3 and the C-terminus of agonist-
bound GPCRs, causing increased affinity between GPCRs and cytosolic arrestins. The 
binding of arrestins to GPCRs will uncouple G proteins from GPCRs, blocking further 
signaling (Penela, Ribas, & Mayor, 2003; Ribas et al., 2007). More studies reveal that 
arrestins and GRKs also mediate the recycling process of GPCRs (receptor 
desensitization, internalization, cytoplasmic trafficking, resensitization and re-
embedding into membrane) by recruiting the vesicle coating protein Clathrin (Lohse, 
Benovic, Codina, Caron, & Lefkowitz, 1990; Moore, Milano, & Benovic, 2007). Along 
with GPCR deactivation, the inherent hydrolytic GTPase activity of Gα converts Gα-GTP 
back to Gα-GDP, which then binds to the Gβγ complex. The reassociation of Gα-GDP and 
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the Gβγ complex terminates all interactions with various effectors and moves the Gαβγ 
complex back to the GPCR IL G-protein-binding site. Thus, a full GPCR activation-
deactivation cycle is completed (McCudden, Hains, Kimple, Siderovski, & Willard, 
2005).  
 
I.1.3 G proteins and signaling 
Heterotrimeric guanine nucleotide binding proteins (G proteins) are membrane-
receptor attached, heterotrimeric, recycling proteins involved in signal transmission. 
Heterotrimeric G proteins have three subunits: alpha, beta and gamma. The G alpha 
subunits are 40-45 kDa proteins consisting of 350-400 amino acids. The G alpha family 
is the key component which determines the functions of each G protein heterotrimeric 
complex. Gα proteins can be divided into 4 subtypes based on their effectors and amino 
acid identity: Gαs, Gαi/Gαo, Gαq/Gα11 and Gα12/Gα13 (Hurowitz et al., 2000). Each family 
contains multiple subtypes which possess different effector binding affinities, specific 
expression patterns and GPCR associations.  
In spite of some exceptions (He et al., 2014), Gαs (stimulatory G proteins) 
generally bind to and activate the 12-transmembrane glycoprotein adenylyl cyclase 
(AC). Activated AC will in turn enzymatically hydrolyze ATP into cyclic adenosine 
monophosphate (cAMP) and pyrophosphate (PPi). cAMP is a secondary messenger 
which regulates many important cellular activities in mammalian cells by activating 
protein kinase A (PKA) (Nature Reviews Drug Discovery, 2004; Wettschureck & 
Offermanns, 2005). 
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Gαi/o (inhibitory G proteins) has a relatively higher expression than other Gα 
proteins, suggesting a higher signal response following activation of Gαi/o -coupled 
receptors. Inhibitory G proteins bind to AC and inhibit its function, causing a drop in the 
cytosolic cAMP level and decreased PKA activity (El-Armouche, Zolk, Rau, & 
Eschenhagen, 2003; E. H. Wu & Wong, 2005). Pertussis toxin (PT) is used in many 
experiments to prevent GαI from binding to GPCRs on the cell membrane by catalyzing 
the Adenosine diphosphate (ADP)-ribosylation of the Gαi subunits. Decreased sensitivity 
to multiple biological stimuli is observed after PT-induced ADP-ribosylations occur on 
different G alpha inhibitory proteins (Mangmool & Kurose, 2011). There are several 
other well established negative regulatory mechanisms of the Gαi/o family, such as 
Gustducin (Gαgust) promotion of the enzyme phosphodiesterases which degrade cAMP to 
5’-AMP in response to activation of certain taste receptors, resulting in inhibition of 
PKA (Clapp et al., 2008; Norton, D'Amours, Grazio, Hebert, & Cote, 2000).  
Four members fall into the G protein q polypeptide (Gαq) family or Gαq/11 because 
these proteins are known to be capable of inducing downstream pathways by activating 
phospholipase C (PLC). PLC is a class of enzymes that catalytically cleave membrane-
bound phosphatidylinositol 4, 5-bisphosphate (PIP2) into inositol 1, 4, 5-trisphosphate 
(IP3) and diacyl-glycerol (DAG). IP3, another important secondary messenger, is then 
dissociated from the membrane and binds to a family of IP3-sensitive receptors (InsP3R) 
on the endoplasmic reticulum (ER), causing an activation of calcium channels and 
release of calcium ions (Ca2+) from the ER into the cytoplasm. Meanwhile, DAG stays 
on the membrane as a secondary messenger which, together with elevated cytosolic Ca2+ 
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levels, activates Protein kinase C (PKC) (Blaukat, Barac, Cross, Offermanns, & Dikic, 
2000; Suzuki, Nakamura, Mano, & Kozasa, 2003; Wettschureck & Offermanns, 2005). 
Gα12 and Gα13 belong to one family Gα12/13, they have a wide expression pattern 
and transduce signals from activated GPCRs to a wide range of functional effectors. In 
most cases, these effectors mediate neither AC nor PLC, but mainly control actin 
cytoskeletal rearrangements or gene expression in mammalian cells by activating Rho 
GTPase signaling (Bishop & Hall, 2000; Hall, 1998, 1999). 
There are 5 Gβ subunits and 12 Gγ subunits identified so far, which contributes to 
a large number of potential Gβγ complex combinations (Gautam, Downes, Yan, & 
Kisselev, 1998; Wettschureck & Offermanns, 2005). Gβ and Gγ form a tightly interacting 
heterodimer which usually serves as a negative regulator and binds to the Gα subunit and 
suppresses its activity when the Gβγ complex is inactive (Dingus et al., 2005). After Gα 
switches to its activated GTP-binding form, freed Gβγ activates its own signaling 
effectors, such as PI-3-K, ACs, PLCs, receptor kinases (RTKs) and GIRKs (Ford et al., 
1998), while maintaining a relatively stable conformation.  
Although there are many aspects about GPCRs that cannot be covered in this 
short introduction, aberrant regulation of any process discussed above is closely related 
with a variety of diseases and cancers (Lappano & Maggiolini, 2011; Vassart & 
Costagliola, 2011).  
 
 8 
 
I.2 Leucine-Rich repeat containing G protein coupled receptors (LGRs) 
LGRs are a class of GPCRs with a large extracellular N-terminal domain which 
is enriched in the hydrophobic amino acid leucine. The Leucine-rich repeats (LRRs) 
form multiple structurally diverse three dimensional segments called Solenoid protein 
domains which usually endow specific ligand-binding affinity to the LGRs (Kobe & 
Kajava, 2001). Roughly 15 years ago, based on phylogenetic analysis and hormone 
screening, three subfamilies of LGRs were identified in vertebrates: the Group A 
glycoprotein hormone receptors including luteinizing hormone receptor (LHR), follicle-
stimulating hormone receptor (FSHR), and thyrotropin receptor (TSHR), the Group B1 
R-spondins (RSPO) receptors LGR4, LGR5 and LGR6, the Group B2 Bursicon-like 
receptor Drosophila LGR2 (DLGR2) and the Group C relaxin (RLXN) and insulin-like 
(ISNL) peptide receptors LGR7, LGR8, GPR142 and GPR 135 (Aittomaki et al., 1995; 
Bathgate, Ivell, Sanborn, Sherwood, & Summers, 2005; Hsu, Liang, & Hsueh, 1998; 
Hsu et al., 2002; C. Liu, Chen, et al., 2003; Minegishi et al., 1990; Scott et al., 2006).  
 
I.2.1 Group A and C LGRs 
LHR and FSHR in Group A are two important receptors mainly expressed in the 
reproductive system, such as ovary, testis and uterus (Dufau, 1998; Simoni, Gromoll, & 
Nieschlag, 1997). LHR and FSHR are receptors for LH and FSH respectively, two 
pituitary secreted heterodimeric glycoprotein hormones which not only share a similar 
structure but also work synergistically in reproduction. The human LHR and rat FSHR 
were first cloned in 1990 (Minegishi et al., 1990; Sprengel, Braun, Nikolics, Segaloff, & 
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Seeburg, 1990), and further functional analysis revealed they play critical roles in both 
male and female germ cell maturation by inducing cAMP signaling through activation of 
Gαs. (Aittomaki et al., 1995; Gromoll, Simoni, & Nieschlag, 1996; Heckert & Griswold, 
1993; Latronico, Abell, et al., 1998; Latronico et al., 1996; Latronico, Chai, et al., 1998; 
Rajagopalan-Gupta, Lamm, Mukherjee, Rasenick, & Hunzicker-Dunn, 1998). The 
finding of several LRRs in the N-termini of LHR, FSHR as well as the TSHR (together 
with more recently identified LGR1, 2, 4, 5 etc.) led to defining LGR as a new subfamily 
of GPCRs (Libert et al., 1989; Nishi, Hsu, Zell, & Hsueh, 2000). 
The relaxin and insulin-like family peptide (RXFP) receptors, also known as the 
Group C LGRs, contain 4 closely related homologues: LGR7 or RXFP1, LGR8 or 
RXFP2, GPR135 or RXFP3 and GPR142 or RXFP4. The Group C members are also 
highly conserved with the Group A LGRs in vertebrate species throughout evolution. 
Although LGR7 was cloned early in 2000 (Hsu et al., 2000), no ligand was found until 
2002, when Sheau Yu Hsu and his colleagues reported LGR8 as a new homologue to 
LGR7. At the same time, relaxin was identified to be a functional ligand for LGR7 and 
LGR8, activating AC/cAMP/PKA signaling (Hsu et al., 2002). Later studies confirmed 
RLXN3 to be a high affinity agonist for LGR7 while ISNL3 is one for LGR8 (Bathgate 
et al., 2005; Kumagai et al., 2002). In 2003, Changlu Liu and his colleagues identified 
another relaxin receptor, GPR135, and its homologue GPR142. Using a 35S labelled 
radioligand 35SGTPγS, they showed that instead of activating cAMP, relaxin 3-induced 
GPR135 and GPR142 activation will in turn inhibit cytosolic cAMP accumulation (C. 
Liu, Chen, et al., 2003; C. Liu, Eriste, et al., 2003). Agonist screening showed that 
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INSL5 has a similar expression pattern and co-evolution with GPR142 and an even 
higher GPR142 affinity than relaxin3 (C. Liu et al., 2005). 
 
I.2.2. Group B LGRs: LGR4, LGR5 and LGR6 
In 1998, Qingyun Liu’s group successfully cloned a 907 amino acid GPCR and 
named it HG38 (McDonald et al., 1998). Later in the same year, an independent group 
also isolated both this receptor, which they named LGR5, as well as another novel 
receptor, LGR4 (Hsu et al., 1998). Two years later, LGR6 and LGR7 were identified 
(Hsu et al., 2000). These studies showed that LGR4, LGR5 and LGR6 have a conserved 
primary structure, such as a relatively large number of LRRs (18 in LGR4 and LGR5, 13 
in LGR6) compared to other LGRs and identical structural alignments between LRRs 1-
7 in LGR6 and LRRs 1-3, 8-11 in LGR4 and LGR5. The rhodopsin-like seven TM 
domains in these receptors are highly conserved as well as the junction region between 
TM1 and the ectodomain, for example these three receptors all have PYAYQCC and 
GXFKPCE motifs on their C terminal cysteine-rich flanking region. The conservation 
between LGR4, LGR5 and LGR6 suggests a similar ligand binding preference and 
function across species (Hsu et al., 2000; Hsu et al., 1998; Loh, Broussard, & 
Kolakowski, 2001).  
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I.2.3 Expression pattern and functions in different organs 
Complete knockout of Lgr4 results in an increased chance of embryonic death in 
multiple mouse strains (Kato et al., 2006; Mazerbourg et al., 2004). To reduce this risk, 
several groups have used genetic engineering strategies, in which a small amount of 
Lgr4 is still expressed which increases the survival rate of Lgr4 ablated mice and 
therefore makes possible to study of the loss-of-function phenotypes in different organs. 
In a gene trap mouse model generated by Philip A. Leighton, the Lgr4 gene is disrupted 
by the insertion of a gene trap vector containing two biological marker genes (LacZ and 
placental alkaline phosphatase (PLAP)) into the first intron of Lgr4 (Leighton et al., 
2001). This insertion results in an expression pattern of the Lgr4 exon 1-bacterial β-
galactosidase fusion protein and PLAP in heterozygous mice (one allele of wide-type 
Lgr4 and one allele of disrupted Lgr4) that mimics the expression pattern of Lgr4 in 
wide-type mice (Van Schoore, Mendive, Pochet, & Vassart, 2005). Van Schoore and 
colleagues showed a broad LacZ activity pattern in heterozygous mice with particularly 
strong activity in adrenal, skin, cartilages, kidneys, reproductive tracts and nervous 
system cells (Van Schoore et al., 2005). LGR5 demonstrated a much more restricted 
expression pattern in mouse hair follicle (Jaks et al., 2008), inner ear (Shi, Kempfle, & 
Edge, 2012), uterus (Sun, Jackson, Dey, & Daikoku, 2009), mammary gland (de Visser 
et al., 2012), kidney (Barker et al., 2012) and gastrointestinal (GI) tract (Barker & 
Clevers, 2010; Barker et al., 2007; W. de Lau et al., 2011). Studies on Lgr6 are still 
limited, with published papers only showing a strong expression in skin (Snippert et al., 
2010) and teeth (Kawasaki et al., 2014). 
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Although the expression pattern of these three receptors varies, it has been shown 
they all have significant effects on organ development. Lgr4-null mice 
(Lgr4Gt(pGTOTMpfs)1Wcs) are associated with embryonic and perinatal death accompanied 
by intrauterine growth retardation (Mazerbourg et al., 2004) and LGR5-null mice  
undergo neonatal death caused by ankyloglossia and gastrointestinal distension (Morita 
et al., 2004), No report so far shows embryonic or neonatal death associated with LGR6 
knockout. The Lgr4 gene trap knockin mouse model mentioned above also shows 
defective development of the kidney, liver (Van Schoore et al., 2005), male reproductive 
tract (Mendive et al., 2006) and small intestine (Mustata et al., 2011), but premature 
ureteric bud development (Mohri, Oyama, Akamatsu, Kato, & Nishimori, 2011). Further 
studies using another gene trap mouse model (Lgr4Gt(LST020)Byg) showed that deletion of 
Lgr4 is related to anterior segment dysgenesis (ASD) of the eye (Weng et al., 2008), 
abnormal eye-lid development (Jin et al., 2008), defective erythropoiesis (Song et al., 
2008), impaired bone formation (J. Luo et al., 2009), increased dextran sodium 
sulfate(DSS)-induced Inflammatory Bowel Disease (S. Liu et al., 2013), delayed 
mammary gland and prostate development (W. Luo et al., 2013; Y. Wang et al., 2013), 
polycystic kidney lesions and renal fibrosis (Dang et al., 2014). In addition, depletion of 
Lgr4 in this mouse model appears to promote the white-to-brown fat transformation 
which regulates energy expenditure (J. Wang et al., 2013). And deletion of Lgr4 in a 
similar gene trap mouse model (Lgr4Gt(pU-21)1Kymm) confirmed the developmental defects 
of the male reproductive tract (Hoshii et al., 2007), as well as demonstrated impaired 
morphogenesis of the gall bladder and cystic duct (Yamashita et al., 2009). Some recent 
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papers show links between these Lgr4-null defects in different organs with stem cell 
regulation (W. Luo et al., 2013; Y. Wang et al., 2013). One recent published paper 
showed that a rare nonsense mutation (c.376C>T) within the LGR4 gene in human 
carriers causes a series of abnormalities which partially overlap the defects observed in 
Lgr4-null mice (Styrkarsdottir et al., 2013). For LGR5, extensive studies have shown 
Lgr5 as an effective marker for Wnt-regulated adult stem/progenitor cell populations in 
proliferative tissue such as the small intestine, colon (Barker et al., 2007), hair-follicle 
(Jaks et al., 2008), uterus (Sun et al., 2009), stomach (Barker et al., 2010), mammary 
gland (de Visser et al., 2012), kidney (Barker et al., 2012), cochlea (Shi et al., 2012) and 
olfactory epithelium (Chen et al., 2014), but limited defects are reported in LGR5-null 
mice. LGR6 positive cells are shown to have a pattern of expression similar to LGR5 in 
skin, and are able to generate all cell lineages of skin epithelium (Snippert et al., 2010). 
 
I.2.4 Tissue specific signaling pathways and their ligands 
As discussed above, LGRs are extremely versatile in terms of their potential 
mechanisms to transmit signals. Group A and C LGRs are known to elevate the cAMP 
level by regulating G proteins, while Group B LGRs are much more complicated. Here I 
will summarize all known signaling pathways of LGR4, 5 and 6 and their ligands. 
LGR4 (also known as GPR48) and LGR5 (also known as GPR49) were 
postulated to have a G-protein interaction domain because of the conserved Glu-Arg-Trp 
triplet motif in the junction between TM3 and IL 2 (Hsu et al., 1998). In 2006, screening 
for the effects of point mutations in the putative G-protein interaction domain, Gao and 
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coworkers found that expression of T755I mutant LGR4 (GPR48-T775I) into HEK293 
cells increased the cAMP level, suggesting that this was a constitutively active form of 
Lgr4 which activates the Gαs-cAMP dependent canonical GPCR pathway (Gao, 
Kitagawa, Shimada, et al., 2006). Extensive following studies revealed that LGR4 
activates downstream pathways through a conserved pathway, Gαs-cAMP-cAMP 
response element-binding protein (CREB), to mediate different transcriptional factors 
(TF) in different tissues. For example, it was reported that Lgr4 regulates Pitx2, a key TF 
in anterior segment development, through the cAMP-dependent canonical GPCR 
pathway mediated by Gαs/cAMP/PKA/CREB (Weng et al., 2008). In definitive 
erythropoiesis and bone remodeling, ATF4 is regulated by Lgr4 through the same 
Gαs/cAMP/PKA/CREB pathway (Song et al., 2008). Also, Lgr4 was reported to 
positively regulate ERα expression in the male reproductive tract through this canonical 
pathway (X. Y. Li et al., 2010). One study shows that through the same 
cAMP/PKA/CREB pathway, the CD14 expression level is significantly increased in 
Lgr4-deficient mice which leads to elevated TLR2/4 associated innate immunity 
regulation (Du et al., 2013). In contrast, most recently a study showed that LGR5 
regulates focal adhesion kinase, NF-κB and c-fos through Gα12/13-Rho GTPase (Kwon, 
Park, Kim, & Kim, 2013). But there is no report so far that shows Gα protein activation 
by LGR6. 
The ligands which activate different canonical pathways downstream of LGR4 
and LGR5 are still unknown. In a Drosophila melanogaster study, Bursicon, a 
glycoprotein-like heterodimeric cysteine knot protein, was found to be able to 
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functionally bind to Drosophila melanogaster LGR2 (DLGR2) and increase the cAMP 
level in vitro (C. W. Luo et al., 2005). Since the Bursicon gene also encodes other 
cysteine-knot domain proteins which resemble bone morphogenetic proteins (BMPs) in 
vertebrate and DLGR2 is orthologous to vertebrate LGR4, 5 and 6, it is predicted that 
the endogenous ligands for LGR4, 5 and 6 are members of the BMP family (Barker, 
Tan, & Clevers, 2013). 
In 1982, in a screen of 12 viral oncogenes, Roel Nusse and Harold Varmus found 
a strong tumorigenic role of mouse mammary tumor virus (MMTV) insertion into a gene 
locus on mouse chromosome 15, and this gene was named int1 (Nusse, van Ooyen, Cox, 
Fung, & Varmus, 1984; Nusse & Varmus, 1982). Several other MMTV provirus favored 
oncogenes were then discovered, including int2 (Peters, Brookes, Smith, & Dickson, 
1983), and int3 (Gallahan & Callahan, 1987). But following studies revealed that int1, 
int2 and int3 are functionally and evolutionarily unrelated (Dickson & Peters, 1987; 
Gallahan & Callahan, 1997; van Ooyen & Nusse, 1984). In addition, a large family of 
int1-related genes were discovered to be expressed widely in adult mice (Christian, 
Gavin, McMahon, & Moon, 1991). Thus the old int1 gene nomenclature is longer viable. 
In 1991, Roel Nusse adopted a new nomenclature in which int1 and int1 related proteins 
become the Wnt family of proteins due to their similarity with proteins encoded by the 
Drosophila melanogaster gene wingless (Rijsewijk et al., 1987), while int2 and int3 were 
renamed as FGF3 and Notch4 respectively. In the past three decades, extensive studies 
have revealed the great importance and versatile biological functions of wnt proteins, 
from drosophila to humans, from embryos to adults, from development to cancer 
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(Clevers & Nusse, 2012; Nusse & Varmus, 2012). The most well studied mechanism of 
wnt signaling is the Wnt/β-catenin pathway or the canonical Wnt pathway, in which the 
wnt proteins carry different signals from outside of cells, with the help of wnt pathway 
co-receptors such as lipoprotein receptor-related protein (LRP)-5/6. Wnt binding to the 
N-terminal extra-cellular cysteine-rich domain of a Frizzled (Fzd) family receptor on the 
cell membrane allows an increase in the cytosolic β-catenin level followed by 
translocation of β-catenin into the nucleus to replace Groucho family co-repressors and 
activation of the transcription factors T cell factor (TCF)/ lymphoid enhancer binding 
factor (LEF) family (Brannon, Gomperts, Sumoy, Moon, & Kimelman, 1997; Cavallo et 
al., 1998; Riese et al., 1997; Staal & Clevers, 2000). The cytosolic β-catenin level is 
regulated through the activity of a “destruction complex” which is constituted of Axin, 
adenomatosis polyposis coli (APC), protein phosphatase 2A (PP2A), glycogen synthase 
kinase 3 (GSK3) and casein kinase 1α (CK1α). Without binding of Wnt proteins to Fzd, 
the destruction complex is free to degrade β-catenin in the cytoplasm, thus Wnt signaling 
pathway is quiescent. With activation of Wnt signaling through binding of Wnt proteins 
to Fzd, a conformational change of the intracellular domain of Fzd will release an 
interacting protein, Dishevelled (Dvl), to the cytoplasm. Dvl works as a suppressor for 
Axin and GSK3 (Penton, Wodarz, & Nusse, 2002; Wagner et al., 1997) and disrupts the 
ubiquitinating ability of the destruction complex, thus stabilizing β-catenin in the 
cytoplasm (Kennell & Cadigan, 2009). The canonical Wnt pathway has been shown to 
play important roles in development and stem/progenitor cells in various organs such as 
the hair follicle (DasGupta & Fuchs, 1999), heart (Naito et al., 2006), kidney (Park, 
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Valerius, & McMahon, 2007; Stark, Vainio, Vassileva, & McMahon, 1994) and lung 
(Goss et al., 2009). In addition, several β-catenin independent Wnt pathways (non-
canonical Wnt pathways) are of great importance in development as well, including the 
Wnt/PCP (Vladar, Antic, & Axelrod, 2009), Wnt/calcium (Kohn & Moon, 2005) and 
Wnt/RTK (Green, Nusse, & van Amerongen, 2014) pathways.  
Notably, R-spondins (RSPOs) and Norrin have also shown the capability of 
potentiating the Wnt/β-catenin pathway. RSPOs consists of 4 members (RSPO1-4) 
which share a conserved domain architecture: two cysteine-rich furin-like domains and 
one thrombospondin (TSP-1) motif. They are widely expressed in vertebrates, but play 
different roles in a tissue-specific manner (W. B. de Lau, Snel, & Clevers, 2012). 
Signaling studies showed that RSPOs are potentiators of Wnt/β-catenin pathway 
activation (Bergmann et al., 2006; Kamata et al., 2004; Kazanskaya et al., 2004; 
Kazanskaya et al., 2008; Nam, Turcotte, Smith, Choi, & Yoon, 2006). Norrin, a secreted 
protein encoded by the Norrie disease gene, shown been shown to enhance Wnt 
signaling by binding to Fzd4 with a high affinity thus regulating development of the 
vasculature in the inner ear and retina (Q. Xu et al., 2004).  
Surprisingly, RSPOs were recently found to be functional agonists of LGR4, 
LGR5 and LGR6, and the R-spondin binding was found to potentiate Wnt/β-catenin 
signaling (Carmon, Gong, Lin, Thomas, & Liu, 2011; W. de Lau et al., 2011; Gong et 
al., 2012). On the other hand, norrin was reported to be the mammalian ortholog for fly 
burs and pburs, and a ligand for LGR4 to regulate the BMP and Wnt/β-catenin pathways 
(Deng et al., 2013; Siwko, Lai, Weng, & Liu, 2013). No significant change has been 
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observed in either heterotrimeric G protein or β-arrestin after RSPO-induced activation 
of LGRs (Carmon et al., 2011; Gong et al., 2012), suggesting a non-canonical GPCR 
pathway is involved in this process. It is worth noting that no LGRs other than LGR4, 5 
and 6 have been found to be receptors for RSPOs, while norrin is able to bind Fzd4. 
Furthermore, successful crystallization of the LGR4 extracellular domain (ECD) and 
RSPOs have provided an insight into the mechanism based on which LGR4, 5 and 6 
recognize RSPOs (D. Wang et al., 2013; K. Xu, Xu, Rajashankar, Robev, & Nikolov, 
2013). Another study showed that RSPO-induced activation of LGR4 and LGR5 
regulate both Wnt/β-catenin as well as Wnt/PCP pathways through Clathrin-dependent 
endocytosis (Glinka et al., 2011). These studies brought attention to a new area in which 
LGR4, 5 and 6 activate downstream signaling through Wnt/β-catenin and the Wnt/PCP 
pathway in a G-protein independent manner. Later studies bring other key components, 
the cell-surface transmembrane E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) and 
ring finger protein 43 (RNF43), into this “non-canonical GPCR pathway” (Hao et al., 
2012). ZNRF3 and RNF43 have been previously demonstrated to be Wnt target genes 
(van de Wetering et al., 2002; Van der Flier et al., 2007; Yagyu et al., 2004) and putative 
negative regulators of the Wnt pathway which is correlated with a high frequency of 
mutation in various types of human cancers (W. de Lau, Peng, Gros, & Clevers, 2014; 
Furukawa et al., 2011; Ryland et al., 2013). The mechanism is described as follows. In 
the absence of RSPO, ZNRF3/RNF43 ubiquitylate Fzd and LRP5/6, leading to 
degradation of these Wnt signaling components. The interactions between RSPOs and 
the ECD of ZNRF3/RNF43 will increase the affinity between ZNRF3/RNF43 and 
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LGR4/LGR5; the binding of ZNRF3/RNF43 to LGR4/LGR5 results in membrane 
clearance of ZNRF3/RNF43; decreased membrane level of ZNRF3/RNF43 leads to 
stabilized LRP6 and Fzd; thus Wnt/β-catenin signaling is potentiated (Hao et al., 2012). 
A more recent study showed that the IQ motif containing Ras GTPase-activating protein 
1 (IQGAP1) is another key component in this complex. The Rspo-induced activation of 
LGR4 signaling increases the affinity between the LGR4-intracellular-domain associated 
protein IQGAP1 and DVL, which further potentiates Wnt signaling (Carmon, Gong, Yi, 
Thomas, & Liu, 2014). 
 
I.3 Breast cancer 
I.3.1 General background 
Breast cancer occurs when a group of cells from the mammary gland become 
more proliferative, invasive and grow out of control, eventually forming a tumor. In 
2014, the estimated number of new cases of breast cancer in female patients is 232,670 
and the estimated number of deaths caused by breast cancer in female patients is 40,000, 
which makes breast cancer the most prevalent and second deadliest cancer in women 
(Breast Cancer Facts & Figures, 2013-2014. 
http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-
042725.pdf). In rare cases, breast cancer also strikes male patients.  
Although acquired (environmental) factors including nulliparity, age, obesity and 
environmental carcinogens have a significant impact on breast cancer progression 
(Tomatis, Melnick, Haseman, Barrett, & Huff, 2001), the hereditary factors remain 
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indispensable. The identification of breast cancer susceptibility genes BRCA1 and 
BRCA2 opened a new area for breast cancer study (Miki et al., 1994; Wooster et al., 
1995). Together with p53 and other genes identified in screening for breast cancer gene 
mutations (Malkin et al., 1990; Shattuck-Eidens et al., 1995), a breast cancer risk 
assessment system was established in which genetic testing of patients and their families 
became theoretical bases for breast cancer prevention and treatment (Biesecker et al., 
1993; "Statement of the American Society of Clinical Oncology: genetic testing for 
cancer susceptibility, Adopted on February 20, 1996," 1996).  
To ensure the best treatment for every individual patient, methods of 
classification based on different categories of features (size, histology, origin of cells, 
DNA profile and membrane receptors etc.) were introduced into clinical diagnoses 
(Raven, 1939a, 1939b). For this purpose, in 1977, The American Joint Committee on 
Cancer (AJCC) proposed a TNM staging system based on tumor size (T), node status 
(N), and metastasis (M) which is being reviewed and modified repeatedly, most recently 
in September 2014. The 7th edition of TNM classifies by the following criteria: primary 
tumor into 5 major categories ranging from T0 (no sign of primary tumor) to T3 
(greatest dimension of primary tumor is greater than 50mm) and in addition T4 (Tumor 
of any size with direct extension to the chest wall and/or to the skin); regional lymph 
nodes status into 4 major categories ranging from N0 (No sign of regional lymph node 
metastases) to N3 (tumor spread to more distant or numerous regional lymph nodes); 
distal organ metastasis status into 2 major categories ranging from M0 (no sign of distant 
metastasis) to M1 (the greatest dimension of distant metastasis is greater than 0.2mm). 
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The combination of the values from these three categories will reflect the current staging 
of breast cancer ranging from 0 to 4. In addition, despite some rare cases (Paget’s 
disease of breast), primary breast cancers can be divided into two major subgroups: 
ductal carcinoma and lobular carcinoma, based on their cells of origin (Haagensen, Lane, 
Lattes, & Bodian, 1978). IDC is the most common type of breast cancer, and it is 
believed to be the most dangerous type of breast cancer, making up 70 to 80 percent of 
breast cancer diagnosed (Borst & Ingold, 1993). Triple negative breast cancer (TNBC) is 
one type of IDC and does not express the receptor tyrosine-protein kinase ErbB-2 
(HER2/NEU) as well as no estrogen receptor (ER) and Progesterone Receptor (PR). It 
spreads much more quickly than other types of breast cancers. In therapeutic treatment, 
TNBC lacks molecularly targeted treatments due to the absence of certain receptor 
expression, is highly resistant to traditional anti-estrogen hormone therapy, and often 
poorly responds to cytotoxic chemotherapy (Bauer, Brown, Cress, Parise, & Caggiano, 
2007). 
Breast cancers are versatile and heterogeneous. In order to have a deep insight 
into the behavior of each cancer type, gene profiles have to be assessed to define specific 
cancer types and their pathological nature. In 2000, Charles Perou and his colleagues 
investigated 8,102 genes by DNA microarrays for their expression patterns in a set of 65 
breast cancer samples from 42 different individuals, based on breast cancer classification 
into 3 subgroups: ER positive/luminal-like, basal-like and ErbB2 positive breast cancer, 
and each type of cancer has its own prognosis and unique molecular portrait (Perou et 
al., 2000). A series of studies showed that the basal-like breast cancer patients have 
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shorter survival times and relapse-free times, and are more likely to form distant 
metastases (Minn et al., 2005; Sorlie et al., 2001; van 't Veer et al., 2002). Triple 
negative breast cancer (TNBC) accounts for 10–25% of all breast carcinomas (Carey et 
al., 2007; Haffty et al., 2006; Reis-Filho & Tutt, 2008). TNBCs make up the majority of 
but do not exactly equal the basal-like carcinoma group (Bertucci et al., 2008; de Ronde 
et al., 2010). Taken together, a breast cancer is a complicated ecosystem involves many 
kinds of entities (e.g. epithelial tumor cell, stromal cell, infiltrating immune cell, 
hematopoietic cell and endothelial cell) which have different roles during tumor 
progression. The cross-talk between each entity has further complicated the situation 
(Meacham & Morrison, 2013).  
 
I.3.2 Use of MMTV-Wnt1 and MMTV-PyMT transgenic mice as breast cancer models  
The Wnt1 gene was overexpressed in MMTV-Wnt1 transgenic mice by mouse 
mammary tumor virus LTR enhancer insertion upstream of the Wnt1 promoter.  This 
insertion leads to constitutive activation of Wnt1 expression in the mouse mammary 
gland which increases the risk for female mice to develop mammary cancer. According 
to previous reports, 50% of female MMTV-Wnt1 transgenic mice develop mammary 
cancer by 6 months of age and metastasis to the lungs is rare (Y. Li, Hively, & Varmus, 
2000). Whereas in our study, in an FVB background, Wnt1 transgenic mice develop 
breast cancer at an average age of 89 days, approximately 15% of Wnt1 transgenic mice 
never develop breast cancer, and 40% of transgenic mice develop lung metastasis. 
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In MMTV-PyMT transgenic mice, PyMT is also controlled by a mouse 
mammary tumor virus LRT enhancer, resulting in mammary gland-specific expression 
of PyMT. The MMTV-PyMT mouse model has a much more robust tumor phenotype 
than the MMTV-Wnt1 model, including multifocal mammary gland adenocarcinoma 
formation, accelerated breast cancer initiation with 100% penetrance, shortened life-
span, and increased metastasis number and size (Guy, Cardiff, & Muller, 1992).  
 
I.4 Stem cells and cancer stem cells (CSCs) 
It has been over 100 years since the term “stem cell” was used in 1908. The first 
experimental evidence related to this term was observed by C.E. Ford in 1956, when he 
reported that the lethality caused by overdose-radiation induced hematopoiesis 
deprivation in mouse can be rescued by bone marrow transplantation (Ford, Hamerton, 
Barnes, & Loutit, 1956). Therefore, together with the discovery of stem cell activity in 
the pig brain (Altman & Das, 1967) and of pluripotential cells in mouse embryos (Evans 
& Kaufman, 1981), the stem cell hypothesis was proposed: there is a rare cell population 
in certain organs that is capable of generating organ-specific mature cells through 
differentiation and maintain its immortality and potency through infinite self-renewal. 
This hypothesis has been best established in hematopoietic studies. Thanks to the 
development of cell flow cytometry technology, the isolation of a specific population 
using a series of cell surface markers from a large mixed pool of cells became possible 
(Fulwyler, 1965; Julius, Masuda, & Herzenberg, 1972). The first isolation of a stem cell 
enriched population was done by Gerald J. Spangrude and his colleagues in 1988, by 
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assessing the expression level of 3 sets of cell surface markers (Thy-1, Sca-1 and lineage 
markers which in this experiment include B220, Gr-1, CD4, CD8 and Mac-1). Cells with 
negative lineage markers, low level of Thy-1 and positive for Sca-1 were isolated from 
mouse bone marrow, and this population was reported to be capable of generating all 
blood cell types after transplantation into a hematopoiesis deprived mouse chimera 
(Spangrude, Heimfeld, & Weissman, 1988). Several studies further confirmed the 
existence of stem cells in hematopoiesis: upon different signaling stimuli, a group of 
high potential stem cells with expression of specific cell surface markers will undergo a 
series of biochemical changes and activate specific transcription factors resulting in 
differentiation into desired blood cell types; at the same time, stem cells perpetuate 
themselves through infinite self-renewal (Orkin & Zon, 2008). 
The phenomena of cancer relapse after tumor incision and metastatic tumor 
formation lead to the suspicion that CSCs exist. The “cancer stem cell” hypothesis is 
derived from the idea of a “stem cell” and proposes that a rare population of tumor cells 
exist within certain cancers, that these cells possess an unlimited self-renewal ability and 
are capable of generating other lineages of cancer cells and reconstituting a new tumor. 
A parallel term, “tumor initiating cells” (TICs) describes a population of cancer cells 
which were enriched for tumorigenesis. By marking tumor cells with different sets of 
fluorescent-conjugated antibodies, populations with enriched tumorigenic ability were 
identified in different types of cancers. The first evidence of CSCs was described in 
human acute myeloid leukemia, in which xenotransplantation of a population of CD34 
positive and CD38 negative human leukemia cells  was reported to be able to cause 
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leukemia in recipient SCID mice (Lapidot et al., 1994); following studies using different 
cell surface markers showed similar results in series of other cancers such as brain 
(Singh et al., 2003), breast (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 
2003), colon (O'Brien, Pollett, Gallinger, & Dick, 2007), ovary (S. Zhang et al., 2008), 
pancreas (C. Li et al., 2007), prostate (Collins, Berry, Hyde, Stower, & Maitland, 2005) 
and melanoma (Schatton et al., 2008). But in all these studies xenograft tumors in 
immune-deficient mice were only generated from thousands of transplanted cancer cells, 
thus debates were raised about the lack of evidence demonstrating that a single cancer 
cell is capable of generating a whole new tumor. In addition, the changed host micro-
environment due to the xenograft may affect tumor growth. Further complicating 
interpretation of xenograft tumor initiation experiments, several reports showed that the 
frequency of tumor initiating cells varies depending on the strain of recipient mouse 
(Joyce & Pollard, 2009; Quail & Joyce, 2013). Using lineage tracing, Hans Clevers’ 
group for the first time demonstrated that one single Lgr5 positive cell can generate 
other cell types in intestinal adenomas while staying at the primary cancer site (Schepers 
et al., 2012). 
Distant metastasis are formed by a small number of disseminated cancer cells 
from a primary tumor, that is to say, to some extent, metastasis initiating cells must 
acquire stemness to generate the secondary tumor (F. Li, Tiede, Massague, & Kang, 
2007). Indeed, the early disseminated cancer cell from distant metastasis are CSC-like 
(Balic et al., 2006), and the metastasis formation requires interactions between CSCs and 
their stem cell niche (Malanchi et al., 2012), and EMT endows differentiated cancer cells 
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with CSC-like properties (Mani et al., 2008; Morel et al., 2008). However, the studies of 
links between CSCs and metastasis are complicated by multiple tumor sites in one 
sample (Pantel, Alix-Panabieres, & Riethdorf, 2009). 
Notably, CSCs also have other characteristics such as quiescence (Graham et al., 
2002; Roth & Fodde, 2011), drug resistance (Dean, Fojo, & Bates, 2005), and radiation 
resistance (Pajonk, Vlashi, & McBride, 2010). All these features allow CSCs to avoid 
traditional cancer therapies and reconstitute tumors. Consequently, targeting CSCs is 
essential for developing effective therapies against cancers that do not respond to 
currently available treatments. 
Characterization of tumor initiating cell-enriched populations in breast cancer has 
shown steady progress. After Al-Hajj and his colleagues enriched human breast cancer 
TICs by selecting CD24-/low/CD44+ (Al-Hajj et al., 2003), a list of cell markers were then 
discovered as human TIC markers in subsequent studies, including ALDH1 (Ginestier et 
al., 2007), ESA (Fillmore & Kuperwasser, 2008), CD133 (Wright et al., 2008),  CK5 
(Kabos et al., 2011), Sox2 (Leis et al., 2012) and some other features (Charafe-Jauffret et 
al., 2009; Lawson, Blatch, & Edkins, 2009). However, the understanding of TIC markers 
in mice is still relatively poor, with Sca-1 in BALB-neuT induced tumors (Grange, 
Lanzardo, Cavallo, Camussi, & Bussolati, 2008), CD61 in mouse mammary tumor virus 
(MMTV)-Wnt1 tumors and p53+/--derived tumors (Vaillant et al., 2008), CD24-/CD90+ 
for TICs of MMTV-Polyoma virus-middle T antigen (PyMT) and MMTV-Wnt1 mice 
(R. W. Cho et al., 2008; Malanchi et al., 2012) and others (Ma et al., 2012). 
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I.5 Metastasis and Epithelial-Mesenchymal transition (EMT) 
             Metastasis has been described and studied for over a century, but understanding 
of the deep mechanism driving metastasis is still limited. Metastasis is the process by 
which cancer cells from a primary tumor undergo multiple alterations resulting in cancer 
cell dissemination mainly into the circulatory system or lymphatic system, arrival in 
distant organs, and formation of a secondary cancer. The most common site for 
metastatic cells to reside are the brain, bone, liver and lung, but metastatic preference 
varies according to different cancer types (Bubendorf et al., 2000; Disibio & French, 
2008; Hess et al., 2006; Nguyen, Bos, & Massague, 2009; Paget, 1889). Upon metastasis 
formation, the function of recipient organs is likely to be interrupted. Therefore, it is 
considered to be the final and the most fatal stage of cancer progression, and around 90 
percent of breast cancer deaths are caused by metastasis (Bendre, Gaddy, Nicholas, & 
Suva, 2003). 
EMT is a process through which an epithelial cell undergoes a series of gene and 
behavior changes accompanied by changes in cell polarity, loss of cell to cell adhesion 
and acquisition of increased migratory as well as invasive ability. EMT was first 
discovered and described during chicken embryogenesis in the 1980s, and then reported 
to be also important in many biological processes such as organ development and 
fibrosis, tissue regeneration and wound healing (Kalluri & Weinberg, 2009). More 
recent studies showed that EMT occurs during cancer metastasis as well (Thiery, 2002). 
To understand this process, the conditions that trigger EMT need to be determined. The 
most predominant change of cells undergoing EMT is loss of E-cadherin expression, 
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which is a membrane protein important for cell adhesion normally expressed in 
epithelial cells (Angst, Marcozzi, & Magee, 2001). Gene profiling identified a list of 
transcriptional factors which are able to induce EMT by regulating their downstream 
gene expression and eventually affect E-cadherin levels upon activation. Among them, 
Snail1, Snail2, zinc finger E-box–binding homeobox (ZEB) 1, ZEB2 and LEF1 are 
found to be able to directly repress the CDH1 promoter, resulting in a decreased level of 
E-cadherin (Batlle et al., 2000; Cano et al., 2000; Eger et al., 2005; Jamora, DasGupta, 
Kocieniewski, & Fuchs, 2003; Remacle et al., 1999). Another EMT-inducing factor 
family, Twist, not only is able to bind to the E-box of CDH1 and inhibit its activity 
(Vesuna, van Diest, Chen, & Raman, 2008) but also directly regulates SNAI2, the human 
gene encoding SNAIL2 (Casas et al., 2011; Yang et al., 2004). In addition to these 
EMT-inducing transcription factors, more signaling pathways are involved in regulating 
EMT, such as the Wnt/β-catenin (Kemler et al., 2004), transforming growth factor 
(TGF) β (J. Xu, Lamouille, & Derynck, 2009), Hedgehog (Omenetti et al., 2008), EGFR 
(Lo et al., 2007), and notch signaling pathways (Z. Wang, Li, Kong, & Sarkar, 2010) as 
well as micro RNA-dependent pathways (J. Zhang & Ma, 2012). All involved pathways 
form a complicated cross-talk network which controls EMT (Gonzalez & Medici, 2014). 
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CHAPTER II  
MATERIALS AND METHODS 
 
II.1 Animals and cell lines 
Animals were maintained in the Program for Animal Resources of the Institute of 
Biosciences and Technology, Texas A&M Health Science Center, and were handled in 
accordance with the principles and procedures of the Guide for the Care and Use of 
Laboratory Animals. All experimental procedures were approved by the Institutional 
Animal Care and Use Committee. 
Lgr4-null mice were generated by microinjection of an Lgr4 gene trap embryonic 
stem cell clone (LST020) from Williams Skarnes (Bay Genomics) into blastocysts of 
C57BL/6 mice (Weng et al., 2008). Lgr4+/- female mice were back crossed to male mice 
of a C57BL/6 background (Charles River, Wilmington, MA) for 5 generations or male 
FVB mice for 12 generations. Inbred FVB Lgr4 null mice were used in prostate 
development and stem cell studies. 
MMTV-Wnt1 mice in a FVB background were kindly provided by Dr. Yi Li 
(Baylor College of Medicine, Department of Molecular and Cellular Biology). Lgr4+/- 
mice of a FVB background were crossed with MMTV-Wnt1 mice to generate MMTV-
Wnt1 Lgr4-/- mice for breast cancer studies. MMTV-Wnt1 Lgr4+/+ litter mates were used 
as controls. 
MMTV-PyMT mice in a FVB background were obtained from The Jackson 
Laboratory. Lgr4+/- mice of a FVB background were crossed with MMTV-PyMT mice 
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to generate MMTV-PyMT Lgr4-/- mice for breast cancer studies. MMTV-PyMT Lgr4+/+ 
litter mates were used as controls. 
All 3-week old FVB/NJ, BLAB/c and B6.Cg-Foxn1nu/J (Nude) mice for 
transplantation and tail vein injection assays were purchased from The Jackson 
laboratory. 
Primers used for genotyping Lgr4 null mice include, 5'-GGT CTT TGA GCA 
CCA GAG GAC ATC-3' (pGT2TMPFS R), 5'-AAA AGC CAC ATT CAA ATC TTA 
GTA ACC-3' (Lgr4 WILD TYPE reverse), 5'-AAG CAC TTG ATG GTC AGA CTA 
CAT GC-3' (Lgr4 WILD TYPE forward). Primers used for genotyping SV40 transgene 
in MMTV-Wnt1 TG mice include 5'-GAA CTT GCT TCT CTT CTC ATA GCC-3' (W-
1 forward), 5'-CCA CAC AGG CAT AGA GTG TCT GC-3' (SV40 reverse). Primers 
used for genotyping in MMTV-PyMT include: 5’-GGA AGC AAG TAC TTC ACA 
AGG G-3’ (forward), 5’-GGA AAG TCA CTA GGA GCA GGG-3’ (reverse). Primers 
used for genotyping in Nude mice include: 5’- CTT CCG CCT TTC TCC TTC AG-3’ 
(forward), 5’-CCT CAT GGA AGT GCC TCT TG-3’ (reverse). 
MDA-231 and MCF7 human breast cancer cell lines were purchased from ATCC 
and cultured in DMEM/high glucose medium with 10% FBS and 1% 
Penicillin/Streptomycin. 
MDA-468 and Hs578T human breast cancer cell lines were kindly provided by 
Dr. Yi Li (Baylor College of Medicine, Department of Molecular and Cellular Biology), 
and cultured in DMEM/high glucose medium with 10% FBS and 1% 
Penicillin/Streptomycin. 
 31 
 
The Wnt2508 mouse breast cancer cell line was kindly provided by Dr. Yi Li 
(Baylor College of Medicine, Department of Molecular and Cellular Biology), and 
cultured in DMEM/F12 medium with insulin, EGF 10% FBS and 1% 
Penicillin/Streptomycin. 
MCF10A cells constitutively expressing ErbB2 and 14-3-3ζ were kindly 
provided by Dr. Dihua Yu (The University of Texas MD Anderson Cancer Center). 
 
II.2 Histology and H&E staining 
II.2.1 Paraffin embedding 
Mammary glands, lungs and tumors were fixed in zinc formalin for 4hrs to 
overnight. Tissues were then dehydrated by: (1) 70% Alcohol, overnight; (2) 2 changes 
of 85% alcohol, 1 hour each;  (3) 2 changes of 95% alcohol, 1 hour each;  (4) 2 changes 
of 100% alcohol, 1 hour each; (5) 50% xylene, 50% alcohol, 20 minutes; (6) 100% 
xylene, 1 hour; (7) 100% xylene, 30 minutes; (8) Paraffin I at 65 oC, 2 hours; (9) 
Paraffin II at 65 oC, overnight; (10) Paraffin III at 65 oC, 30 minutes. Tissue specimens 
were embedded in paraffin and sectioned at 3 µm. 
 
II.2.2 H&E staining 
3µm sections were incubated (1) at 65 oC for 1~2 hours; (2) 100% xylene I, 5 
minutes; (3) 100% xylene II, 5 minutes; (4) 100% xylene III, 5 minutes; (5) 2 changes of 
100% alcohol, 2 minutes each; (6) 2 changes of 95% alcohol, 2 minutes each; (7) 70% 
alcohol for 2 minutes; (8) distilled water, 1 minute.  
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Sections were then stained in hematoxylin solution (Sigma Co, St. Louis, MO) 
for 3-5 minutes, rinsed with running hot water 5 times, incubated in 70% alcohol for 2 
minutes, Counterstained in Eosin solution (Sigma Co, St. Louis, MO) for 20~40 
seconds, placed in 2 changes of 95% alcohol, 2 minutes each followed by 2 changes of 
100% alcohol, 2 minutes each and cleared in 3 changes of xylene, 5 minutes each. Slides 
were then mounted with xylene based mounting medium (Thermo Fisher Scientific, 
Waltham, MA). 
 
II.3 LacZ staining 
Tumor LacZ staining was performed in mammary glands and breast tumors at 
indicated ages. Mammary glands and breast tumors were fixed in freshly made fixative 
solution (0.2% glutaraldehyde, 5mM EGTA, 2mM MgCl2, 2% formaldehyde in 0.1M 
phosphate buffer PH7.3) for 1 hour at room temperature. After 3 washes in freshly made 
wash buffer (0.1% deoxycholic acid, 2mM MgCl2, 0.2% NP40 in 0.1M phosphate buffer 
PH7.3) for 30 minute each, samples were incubated in staining solution (1mg/ml X-gal, 
5mM potassium ferricyanide, 5mM potassium ferrocyanide in wash buffer) overnight at 
room temperature.  
Hematoxylin staining was performed on 3 µm LacZ sections. Sections were (1) 
incubated at 65 oC overnight to removed paraffin roughly; (2) 3 changes in 100% xylene, 
2 minutes each; (3) 2 changes of 100% alcohol, 30 seconds each; (4) 2 changes of 95% 
alcohol 30 seconds; (5) 70% alcohol for 1 minute; (6) stain in Hematoxylin solution for 
30 seconds. (7) 2 changes of 95% alcohol, 30 seconds each; (8) 2 changes of 100% 
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alcohol, 30 seconds each; (9) Clear in 3 changes of xylene, 30 seconds each; (10) Mount 
with xylene based mounting medium. 
 
II.4 Immunohistochemistry 
II.4.1 Antibodies  
Antibodies used for immuno-histochemistry include: mouse monoclonal 
Cytokeratin 8 antibody (Fitzgerald, Acton, MA, 1:200), rabbit monoclonal anti-
Cytokeratin 5 antibody (Abcam plc, Cambridge CB4 0FL, United Kingdom, 1:250),  
Mouse monoclonal anti-p63 antibody (Abcam plc, Cambridge CB4 0FL, United 
Kingdom, 1:200), mouse monoclonal anti-PCNA antibody (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, 1:100); rabbit polyclonal anti-Ki67 antibody (Novus, Littleton CO, 
1:100); mouse monoclonal anti-E-cadherin  antibody (Abcam plc, Cambridge CB4 0FL, 
United Kingdom, 1:200); mouse monoclonal anti-Cytokeratin 18 antibody (Abcam plc, 
Cambridge CB4 0FL, United Kingdom, 1:100). 
 
II.4.2 IHC staining 
3 µM sections were first deparaffinized and rehydrated as described in H&E 
staining steps (1) through (8). Sections were then washed in PBS for 5 minutes. Antigen 
retrieval was achieved by boiling sections in 10 mM sodium citrate (PH 6.0) for 15~20 
min. Sections were then treated with 3% H2O2 for 15 min at room temperature to reduce 
endogenous peroxidase activity. Avidin/biotin blocking kit (Vectorlabs, Burlingame, 
CA) was used to reduce background staining. Immunostaining was performed using the 
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Vectastain Elite ABC system (Vectorlabs, Burlingame, CA) and VECTOR NovaRED 
Peroxidase Substrate Kit (Vectorlabs, Burlingame, CA) according to protocols provided. 
Sections were incubated with primary antibody overnight at 4 oC. Nuclei were then 
counter stained with hematoxylin for 5-10 minutes. Finally, sections were dehydrated 
and mounted by: (1) Rinsing with running hot water for 5 times; (2) 70% alcohol for 2 
minutes; (3) 2 changes of 95% alcohol, 2 minutes each; (4) 2 changes of 100% alcohol, 
2 minutes each; (5) Clearing in 3 changes of xylene, 5 minutes each; (6) Mount with 
xylene based mounting medium. 
 
II.5 Dissociation of breast primary tumors 
  Primary breast tumors were excised from euthanized MMTV-Wnt1 tumor-
bearing mice at indicated ages. Tumors were digested using the following steps: (1) 
Mince 0.5 cm3 tumor into small pieces no bigger than 2 mm3; (2) resuspend minced 
tumor with 10 mL Medium 199 containing 0.2% FBS; (3) add 50 units of DNase I 
(Sigma-Aldrich, St. Louis, MO), 8 units of Liberase TH (Roche Applied Science, 
Indianapolis), and incubate at 38 oC for 2 hours, pipetting every 30 minutes; (4) add 
another 50 units of DNase I, incubate 30 minutes; (5) add 40 mL RPMI medium 
containing 10% FBS to inactivate DNase I and Liberase TH; (6) filter all cells using 40 
µM nylon cell strainer (BD Biosciences, San Jose, CA); (7) centrifuge for 5 minutes, 
carefully aspirate and discard the supernatant without disturbing the pellet; (8) resuspend 
pellet with 5 mL Red blood cell lysis buffer (eBioscience, San Diego, CA), and incubate 
at room temperature for 5 minutes to remove red blood cells; (9) add 10 mL HBSS 
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medium containing 2% FBS to dilute red blood cell lysis buffer; (10) filter all cells using 
40 µM nylon cell strainer, centrifuge for 5 minutes, remove supernatant and resuspend 
pellet in 2 mL HBSS medium containing 2% FBS. 
 
II.6 Cell staining and flow cytometry  
All antibodies in this procedure were from eBioscience, San Diego, CA. Single 
primary breast cancer cell suspension was stained with 5 biotin-conjugated cell lineage 
markers (2 µL for each antibody): anti-mouse TER-119 (Ly-76), anti-mouse Ly-6G (Gr-
1), anti-mouse CD11b, anti-mouse/human CD45R (B220) and anti-mouse CD3e; 
0.1µg/200µl Streptavidin eFlour 450, 0.2µg/200µl Anti-Mouse CD24 (HSA) APC and 
0.2ug/200ul Anti-Rat/Mouse CD90 (Thy-1) PE in 1% BSA in PBS for 0.5 hour. After 
staining, cells were washed with 1% BSA in PBS 3 times and re-suspended 0.5ml 1% 
BSA in PBS.  FACS analysis was done by using the BD FACS Canto and CellQuest 
software. Cell sorting was conducted by BD FACS Vantage (BD Biosciences, San Jose, 
CA). Data from a minimum of 10,000 cells of each sample was recorded for analysis. 
The cell counter of the flow cytometers was used to determine cell numbers. Small 
samples of the triple-sorted and GFP-sorted cells were reanalyzed for purity. Final cell 
purity was greater than 95%. Pellets of cancer cells were resuspended in 4% PFA for 
fixation before flow cytometry in analysis-only experiments.  
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II.7 Limiting dilution assay 
FVB/NJ or Nude female mice (2 months of age) were sedated by isoflurane 
(Abbott Laboratories, North Chicago, Illinois) through a KSC Tabletop Anesthesia 
System (Kent Scientific Corporation, Torrington, Connecticut). The number of cells 
injected in each group was calculated based on pilot experiments. Sorted cells or 
digested primary tumor cells or breast cancer cell lines were suspended in 50 µL of 
indicated medium and then well mixed with 50 µL growth factor reduced Matrigel (BD 
Biosciences, San Jose, CA). Mixed cells were injected orthotopically into the right 4th 
mammary gland of Nude mice using a 271/2-gauge tuberculin syringe (BD Biosciences, 
San Jose, CA). 
 
II.8 Tail vein injection and luciferase assay 
Nude female mice (2 months of age) were sedated by isoflurane (Abbott 
Laboratories, North Chicago, Illinois) through a KSC Tabletop Anesthesia System (Kent 
Scientific Corporation, Torrington, Connecticut). Mouse tails were soaked in warm 
water to dilate tail veins. GFP or luciferase labeled MDA-231 were suspend in PBS and 
injected into dilated tail veins. 2x105 MDA-231 cells stably expressing luciferase as well 
as either shControl or shLGR4 were injected into the tail vein of each of 5 female 
BALB/c nude mice per shRNA. The lung bioluminescence photon values were 
monitored on days 0, 10, 20, and 30 using the IVIS 200 System (Xenogen/Perkin Elmer, 
Boston, MA, USA). The lungs were isolated, fixed and H & E stained after mice were 
euthanized. 
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II.9 Virus preparation and cell line infection 
We adopted a protocol from the Lamia laboratory (Department of Chemical 
Physiology, The Scripps Research Institute) to generate virus (The Lamia Lab Viral 
Production and Infection Protocol, 
http://www.scripps.edu/lamia/Lamia_website/Protocols_files/VirusProduction%26Infect
ionJan2012.pdf) using a calcium phosphate transfection kit (Clontech Laboratories, 
Mountain View, CA) and minor modifications. General steps are described as following: 
(1) 293T cells were grown in DMEM/high glucose medium with 10% FBS until 50% 
confluent; (2) transfected 6.4 µg psPAX, 3.6 µg pMD2.G and 5 µg target plasmid (5 
different Lgr4 knockdown vector purchased from Thermo Fisher Scientific, Waltham, 
MA) per 10 cm dish into 293T; (3) changed to fresh medium with puromycin (10 µg/ml) 
for selection; (4) culture medium was collected and filtered with 0.4 µM strainer to 
remove cell debris once per day for 3 days after transfection; (5) MDA-231 or Wnt2508 
breast cancer cell lines were infected with collected virus medium for 2 hours and 
changed to fresh medium every day for the next 3 days; (6) titration was measured at the 
end of the 3rd infection. 
 
II.10. In vitro tumorsphere assay 
10,000 cells from digested primary tumor or 1,000 cells of breast cancer cell 
lines were cultured in sphereculture medium for tumorsphere formation. Each generation 
of primary tumorspheres was cultured for 18 days, each generation of breast cancer cell 
line tumorspheres was cultured for one week. When passaging tumorspheres, Matrigel 
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was dissociated by 1mg/ml Dispase (Life Technologies, Carlsbad, CA) for 45 minutes at 
37 oC. After washing with PBS, tumorspheres were dissociated with 0.25% Trypsin-
EDTA 37 oC for 15 minutes, pipetting up-and-down every 5 minutes. To obtain a single 
cell suspension, Trypsin treated tumorspheres were passed through a 40 µm cell strainer 
and resuspended in sphereculture medium.  
 
II.11 In vitro 3D culture assay 
The general protocol for In vitro 3D culture assay we adopted was published on 
Science Direct (Jayanta Debnath 2003). Minor changes are described as follows: 6 well-
plate was pretreated with a small volume of Matrigel to form a thin layer of “bed”. 50 µl 
of MCF10A-ErbB2-14,3,3 cell suspension at indicated concentration was mixed with 
50 µl growth factor reduced Matrigel and seeded on the Matrigel bed. After Matrigel 
was solidified at 37 oC for 30 minutes, 2 mL of breast cancer 3D culture Medium was 
added to the culture. Medium was changed twice a week.   
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Table 1 Quantitative PCR primers 
Sequence Name Bases Sequence 
mCdh1 RT F 24 TCA CAG TGA AGC GGC ATC TAA AGC 
mCdh1 RT R 24 ACC AGG TTC TTT GGA AAT TCG CCC 
mVimenitin RT F 24 ATC ATG CGG CTG CGA GAG AAA TTG 
mVimenitin RT R 24 TTC TTG GCA GCC ACG CTT TCA TAC 
mSnail RT F 26 TTG TAA CAA GGA GTA CCT CAG CCT GG 
mSnail RT R 24 TCT CTT CAC ATC CGA GTG GGT TTG 
mb-catenin RT F 23 ACT GGC AGC AGC AGT CTT ACT TG 
mb-catenin RT R 22 AAT TGC ACG TGT GGC AAG TTC C 
mSox2 RT F 24 ATG AGA GCA AGT ACT GGC AAG ACC 
mSox2 RT R 24 TCG GCA GCC TGA TTC CAA TAA CAG 
m36B4 F 21 GGC ATC ACC ACG AAA ATC TCC 
m36B4 R 21 AAT GCA GAT GGA TCA GCC AGG 
mLgr4 F 22 AAC AGT ACC CAG TGA AGC CAT T 
mLgr4 R 22 GAT GTT GTC ATC CAG CCA CAG A 
mLrp5 RT F 24 ACC TCA GCA TTG ACA TCT ACA GCC 
mLrp5 RT R 24 TTC GAT TCG CTT TAG GTC GGC ATC 
mb-catenin RT F 23 ACT GGC AGC AGC AGT CTT ACT TG 
mb-catenin RT R 22 AAT TGC ACG TGT GGC AAG TTC C 
mLrp6 RT F 26 GTG ACA TCC ATG CAG TAA AGG AGC TG 
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Table 1 Quantitative PCR primers (Continued) 
mLrp6 RT R 24 ATC TGA TTT GTC CTG GCA GTT CGC 
mAxin2 RT F 24 TTC CTG ACC AAA CAG ACG ACG AAG 
mAxin2 RT R 24 TAA CAT CCA CTG CCA GAC ATC CTG 
mWnt2 RT F 24 ACA ACA ACA GAG CTG GAA GGA AGG 
mWnt2 RT R 24 ATG TGT CAT AGC CTC TCC CAC AAC 
mWnt4 RT F 24 AAA CGG AAC CTT GAG GTG ATG GAC 
mWnt4 RT R 24 ACG TCC ACA AAG GAC TGT GAG AAG 
mWnt5a RT F 24 TTT GGC AGG GTG ATG CAA ATA GGC 
mWnt5a RT R 24 TGT AAG TTC ATG AGG ATG CGT GCG 
mWnt10a F 21 GAA CAA AGT CCC CTA CGA GAG 
mWnt10a R 20 CCT TCA GTT TAC CCA GAG CG 
mCyclin D1 F 24 TGG AAC TGC TTC TGG TGA ACA AGC 
mCyclin D1 R 24 TCT GGA AAG AAA GTG CGT TGT GCG 
hMMP3-F 24 TGA GGA CAC CAG CAT GAA CCT TGT 
hMMP3-R 24 ACC AAC ATC AGG AAC TCC ACA CCT 
hMMP11-F 24 ACT CAC CTT TAC TGA GGT GCA CGA 
hMMP11-R 24 AGG GCT GGC CAT ATA GGT GTT GAA 
hLGR4-F 24 AGG CCT TGT CTG GGT TGA AAG AAC 
hLGR4-R 24 TGC AGA ACT ACC AGG CTT GAA AGG 
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II.12 RNA collection, cDNA synthesis and Quantitative PCR 
0.1 cm3 breast tumor was soaked in liquid nitrogen and milled into tissue powder, 
1 mL Trizol LS reagent (Life Technology, Carlsbad, CA) was then added to lyse the 
tissue. 90% confluent breast cancer cell lines were lysed by adding 1 mL Trizol LS 
reagent per 10 cm plate. Total RNA was then extracted by the following steps: (1) 
Incubate at room temperature for 5 minutes; (2) Collect lysate into a 1.5 mL RNase-free 
Eppendorf tube and centrifuge at 12,000 rpm for 5 minutes, transfer supernatant to a new 
RNase-free tube; (3) Add 200 µL chloroform, mix thoroughly with votexing, incubate at 
room temperature for 15 minutes; (4) 12,000 rpm centrifuge at 4 oC for 15 minutes; (5) 
Carefully remove the aqueous phase of the sample and pipetting the solution into a new 
RNase-free tube without making any contact with the interphase or organic layer; (6) 
Add 500 µL isopropanol, mix thoroughly and incubate at room temperature for 5 
minutes; (7) 12,000 rpm centrifuge at 4 oC, discard supernatant; (8) Wash RNA pellet 
with 1 mL 70% ethanol; (9) 8,000 rpm centrifuge at 4; (10) Dissolve RNA pellet with 50 
µL RNase-free water, and proceed to determine RNA concentration and 260/280 ratio 
measurement using Bio-Red SmartspecTM Plus spectrophotometer (Bio-Red, Hercules, 
CA) 
2µg RNA was annealed to 1µg Oligo (dT) 15 Primer (Promega, Madison, WI) at 
70 oC for 5 minutes. Samples were put on ice immediately for 5 minutes and then 
subjected to cDNA synthesis by 200unit/reaction M-MLV Reverse transcriptase 
(Promega, Madison, WI) for 50 minutes at 42 oC. Reverse transcriptase was inactivated 
at 75 oC for 15 minutes. 
 42 
 
cDNA was diluted at 1:10 and 1µL was subjected to each quantitative PCR 
reaction. Real time quantitative PCR was done with GoTaq® qPCR Master Mix 
(Promega, Madison, WI). Quantitative PCR was performed on Mx3000P QPCR System 
(Agilent Technologies, Santa Clara CA) and with MxPro QPCR Software (Agilent 
Technologies, Santa Clara CA). The ratio between expression levels in the two samples 
was calculated by relative quantification, by using housekeeping genes 36B4 in mouse 
QPCR and β-actin in human QPCR as reference for normalization. 
 
II.13 Trans-well invasion assay 
Growth factor reduced Matrigel (BD Biosciences, San Jose, CA) was mixed with 
serum free MEM Eagle medium at 1:4. 100µl of the mixture was added to the bottom of 
cell culture insert with 8µm pore (BD Biosciences, San Jose, CA).  Cell culture inserts 
were incubated at 37 oC for 1 hour.  
Cells were serum starved in DMEM/high glucose medium containing 0.2% FBS 
for 12 hours. Starved cells were pre-treated with mytomycin C (Sigma Co, St. Louis, 
MO) at 20ug/ml for 4 hours. Starved cells were harvested and resuspended at 
1×105cells/ml in DMEM/high glucose medium containing 0.2% FBS. 100µl of cell 
suspension was seeded into cell culture insert with Matrigel at bottom. 500µl complete 
DMEM/high glucose medium containing 10% FBS was added to lower chamber. 10% 
FBS was served as chemo-attractant.  
Cell invasion was checked every 12 hours until a significant amount of cells 
invaded through 8µm pore on cell culture insert. Remove cells from the top of the filter 
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with cotton swab. Cells at the bottom of the insert were fixed by immersing cell culture 
inserts into 4% paraformaldehyde for 15 minutes at room temperature. Cell culture 
inserts were then washed in PBS. Invaded cells were stained with 0.05% Crystal Violet 
(Sigma Co, St. Louis, MO) in distilled water for 30 minutes. After 2 washes in PBS, 
invaded cells were visualized under microscope.   
 
II.14 In vivo tumor size determination 
Primary MMTV-Wnt1 tumors or xenograft tumors were measured by calibration 
ruler. We defined the day palpable tumors were detected as day 0, the width (W) and 
length (L) of tumors were measured and recorded once a week. To calculate the Volume 
of tumors (V), the function was adopted: V=L*W2. 
 
II.15 Western blot 
Cells were starved overnight in DMEM/high glucose medium containing 0.2% 
FBS and washed twice by 4 oC PBS before cell lysis. Cell lysate was collected by RIPA 
buffer (10mM Tris, PH 7.2, 0.1% SDS, 0.1% v/w Triton X-100, 0.1% Deoxycholate, 
5mM EDTA) with protease inhibitor cocktail (EMD Millipore Corporation, Billerica, 
MA). After protein concentration was determined by Micro BCA Protein Assay Kit 
(Thermo Fisher Scientific, Waltham, MA), the Western blot procedure was carried out 
as described in the protocol obtained online (Western blotting - a detailed guide, 
Abcam). 
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II.16 Drug resistance assay 
MDA-231 breast cancer cell line was infected with ShLgr4 or ShControl virus. 
After knockdown efficiency was measure, cells were trypsinized and seeded into 96 
well-plates with the cell concentration of 10,000 per well. Cells were cultured in 
DMEM/high glucose medium containing 10% FBS for 6 hours and then starved in 
DMEM/high glucose medium with 0.2% FBS for 4 hours. Starved cells were then 
treated with indicated concentrations of Doxorubicin or Docetaxel in 10% FBS 
containing fresh medium for 12 hours. Remove the medium and proceed to growth curve 
determination. 
 
II.17 Growth curve 
10,000 cells were seeded and cultured overnight in DMEM/high glucose medium 
with 10% FBS. Cells were serum starved for 4 hours before experiments. After RSPO2 
or wnt3a or drug treatments, the cell number was determined by MTT based in vitro 
toxicology assay kit (Sigma Co, St. Louis, MO). 
 
II.18 Wound healing assay 
Cells were cultured in 6 well plate until 100% confluent, followed by overnight 
starvation in medium containing 0.5% FBS. Starved cells were pre-treated with 
mytomycin C (Sigma Co, St. Louis, MO) at 20ug/ml for 4 hours.  A wound was made by 
scratching cells with a 10 µL tip. Cells were then washed with PBS twice and migration 
 45 
 
was induced by complete medium containing 10% FBS. Cell migration was checked 
every 12 hours. 
 
II.19 Statistics 
Statistical analysis on single gene expression was performed using Student’s T-
test between the two groups. p value equal or less than 0.05 was considered significant. 
Comparison of multiple gene expressions in qPCR experiment was performed using 
Holm’s test. The tumor free curve was carried out by Kaplan-Meier estimate (Goel, 
Khanna, & Kishore, 2010). 
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CHAPTER III 
RESULTS 
 
III.1 Lgr4 is highly expressed in several breast cancer cell lines and primary MMTV-
Wnt1 tumors 
To investigate the function of Lgr4 in breast cancer, we first assessed Lgr4 
expression both in vivo and in vitro. First, in an analysis of a published human breast 
cancer microarray database (Y. Wang et al., 2005), LGR4 expression is elevated in 
human breast cancer patient samples. High expression of LGR4 in human breast cancer 
patients is correlated with high risk of cancer recurrence (Figure 1 A), increased distant 
metastasis formation (Figure 1 B) and poor overall survival rate (Figure 1 C).  
Lgr4 has previously been implicated in cell invasion in colorectal and several 
cancer cell lines (Gao, Kitagawa, Hiramatsu, et al., 2006; J. Wu et al., 2013). We 
therefore examined whether Lgr4 expression in a panel of breast cancer cell lines would 
correlate with the relative invasive capability of each cell line. By using QPCR, six 
different human breast cancer cell lines were tested for LGR4 mRNA level. The invasive 
and TNBC cell lines tended to have a relatively higher expression of Lgr4 than other 
breast cancer subtypes (Figure 1 D), suggesting that the correlation between 
invasiveness and Lgr4 expression extends to breast cancer.  
In the mouse study, we used an Lgr4 gene-trap mouse model. In this mouse 
model, the CD4 transmembrane domain is fused with the β-galactodase gene in a gene 
trap vector that also contains the placental alkaline phosphatase gene behind an IRES, 
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and the gene trap was inserted between exon1 and exon2 of the Lgr4 gene (Weng et al., 
2008). The insertion results in disruption of Lgr4 transcription and expression of the 
biochemical markers Lac-Z and PLAP which allows examination of the Lgr4 expression 
pattern by Lac-Z staining in Lgr4+/- mice. The insertion was confirmed by Southern blot, 
and genotyping of the experimental mice was done as described in materials and 
methods. We have previously published the expression pattern of Lgr4 in the normal 
mammary gland in adult mice (Y. Wang et al., 2013), where Lgr4 is expressed in most 
basal epithelial cells. Three MMTV-Wnt1 Lgr4+/- mice with Wnt1 tumors were 
sacrificed at the age of 5 months, and Lac-Z staining was performed on these tumors; 
one Wnt1 tumor from Lgr4+/+ mouse at the age 5 months was also stained for Lac-Z 
activity as a negative control. The Lac-Z staining in MMTV-Wnt1 hyperplastic 
mammary gland showed that a rare (around 7%) population were Lgr4 positive cells, 
and all p63-positive cells were also Lgr4 positive (Figure 1 E) which supported our 
previous report (Y. Wang et al., 2013). Furthermore, the Lgr4 level is elevated in 
MMTV-PyMT induced breast cancer when compared with normal mammary gland 
(Figure 1 F). Taken together, these results suggest that Lgr4 may play an important role 
in breast cancer progression. 
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Figure 1 Lgr4 affects relapse, metastasis and survival of breast cancer patients 
A, C & D) 286 human breast cancer patients reported in the database described by Wang 
et al. (Y. Wang et al., 2005) were segregated into two groups based on relative tumor 
LGR4 mRNA expression and subsequent relapse (A), distant metastasis (C) and overall 
survival (D) were analyzed. Patients with tumors expressing high levels of LGR4 had 
significantly worse outcomes in all three metrics. B) mRNA level of LGR4 in 6 different 
human breast cancer cell lines. Cell lines with weak invasion ability are marked blue; 
cell lines with strong invasion ability are marked red. Bar graph shows that the relative 
expression level of LGR4 mRNA in three highly invasive cell lines are significantly 
higher than 3 poorly invasive cell lines. Error bar shows the standard deviation between 
PCR reaction triplicates. E) In hyperplastic mammary gland, Lgr4 expression (shown by 
LacZ staining) is partially co-localized with p63 (shown by Immunohistochemistry). 
Arrows indicate Lgr4 and p63 co-localization. F) Bar graph shows relative mRNA level 
± S. E. of Lgr4 in normal breast tissues and tumors from 7-week old MMTV-PyMT 
mice. A-D courtesy of Ying Wang. 
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Figure 2 Tumor growth in breast cancer mouse models is delayed by loss of Lgr4 
A) The age at which MMTV-Wnt1 mice develop palpable breast cancers. Mice were 
palpated twice every week after weaning; the age of the mice at detection of palpable 
tumors (usually 0.3 cm at greatest dimension) was recorded (T1), *** p≤0.001 B) The 
length of time for MMTV-Wnt1 tumors to grow from initial detection to 1.5 cm length at 
greatest dimension. The tumors were measured once every week. Once the tumor size 
reached 2 cm at greatest dimension, the mice were sacrificed and the ages of mice were 
recorded (T2), **p≤0.01, ***p≤0.001 C) Breast tumor volumes were compared between 
Lgr4+/+, Lgr4+/- and Lgr4-/- MMTV-Wnt1 tumors. The breast tumor width (W) and 
length (L) were measured in Lgr4+/+, Lgr4+/- and Lgr4-/- MMTV-Wnt1 tumors once a 
week, and tumor size (V) was calculated using the function: V=L*W2. Using the 
equation: V=L*W2. D) The Kaplan–Meier estimate showing MMTV-PyMT tumor free 
rate in Lgr4+/+, Lgr4+/- and Lgr4-/- mice, courtesy of Ying Wang.  
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III.2 Lgr4 depletion significantly delays tumor growth in MMTV-Wnt1 and MMTV-
PyMT mice 
In our preliminary observations, MMTV-Wnt1 Lg4-/- and MMTV-PyMT Lg4-/-  
mice with genotype have a much slower growth of mammary cancer than the 
corresponding Lgr4+/+ mice. To investigate the effect of Lgr4 ablation on Wnt1-driven 
tumor growth, we observed 86 MMTV-Wnt1 mice with different Lgr4 genotypes (33 
Lgr4+/+ mice, 37 Lgr4+/- mice and 6 Lgr4-/- mice) from date of birth (DOB), through 
time of tumor initiation (T1) to length of time for tumor growth from initiation to 2 cm at 
greatest dimension (T2). Based on published data, half of MMTV-Wnt1 wild-type mice 
with an SJL strain background start to develop tumors at an age of 6 months and the rest 
develop tumors in the following half a year (Y. Li et al., 2000). In our study all MMTV-
Wnt1 TG mice are in a FVB background, Lgr4+/+ mice have an average of 89 ± 43 days 
to T1 and 15.6% (N=5) of mice do not develop palpable tumors by the age of 1 year; 
Lgr4+/- showed an delayed development over Lgr4+/+ with an average of 140 ± 39 days 
to T1 and 24.3% (N=9) of mice do not develop palpable tumors by the age of 1 year. 
MMTV-Wnt1 Lgr4-/- mice have an average of 67 ± 39 days to T1 and all 6 Lgr4-/- mice 
developed tumors before 160 days (Figure 2 A). Therefore, loss of Lgr4 appeared to 
accelerate the initial appearance of mammary tumors in MMTV-Wnt1 mice, although 
our numbers of MMTV-Wnt1 Lgr4-/- mice are too small to draw a firm conclusion on 
this point. When comparing T2, MMTV-Wnt1 Lgr4+/+ mouse tumors have an average 
time of 39 ± 10.2 days to grow from initial detection to 2cm at the largest dimension; 
MMTV-Wnt1 Lgr4+/- mice have an average of 50 ± 15.3 days; while MMTV-Wnt1  
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Lgr4-/- mice have an average of 68 ± 9.1 days (Figure 2 B).  Furthermore, the tumor size 
in MMTV-Wnt1 Lgr4+/+ tumors grew significantly faster than MMTV-Wnt1 Lgr4-/- 
tumors (Figure 2 C). It suggests that the Lgr4 expression level correlated with the speed 
of tumor growth in MMTV-Wnt1 mice. Meanwhile, compared to MMTV-PyMT Lgr4+/+ 
mice, haploinsufficiency of Lgr4 in MMTV-PyMT mice is enough to increase the T1 by 
33 days (Figure 2 D). 
We next sought to determine whether cancer progression is affected by Lgr4. The 
tumor histology, assessed by H&E staining, was compared between MMTV-PyMT 
Lgr4+/+ and MMTV-PyMT Lgr4-/- in different stages of breast cancer for tumor 
progression. Pathologistic studies showed MMTV-PyMT Lgr4+/+ mice started to develop 
hyperplasia by the age of 6 weeks, MMTV-PyMT Lgr4+/- started by the age of 9 weeks, 
while Lgr4 showing no sign of hyperplasia development (Figure 3). Meanwhile, 
MMTV-Wnt1 Lgr4-/- mammary glands showed a decreased hyperplasia formation 
compared to MMTV-Wnt1 Lgr4+/+ (Figure 4 A).  Therefore, tumor progression in 
MMTV-Wnt1 and MMTV-PyMT correlated with Lgr4 expression level. 
In order to study whether Lgr4 ablation leads to decreased tumor size and 
delayed cancer progression, proliferation of epithelial cells was determined by 
immunohistochemical staining of the proliferation marker Ki67 in MMTV-Wnt1 tumors 
(Figure 4 B). The frequency of Ki67 positive cells in MMTV-Wnt1 Lgr4+/+ tumors was 
33 ± 7.4 per hundred cells, and the number in MMTV-Wnt1 Lgr4-/- tumors was 
decreased to 17.3 ± 5.6 per hundred cells (Figure 4 C). Therefore, mammary tumor 
proliferation is reduced in the absence of Lgr4. 
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III.3 Lgr4 ablation decreases CSC numbers in MMTV-Wnt1 tumors and several breast 
cancer cell lines  
Lgr4 knockout leads to a decreased number of stem cells in the mammary gland 
and impaired prostate stem cell differentiation (W. Luo et al., 2013; Y. Wang et al., 
2013). In order to investigate whether the attenuated tumor size and delayed cancer 
progression in MMTV-Wnt1 Lgr4-/- and MMTV-PyMT Lgr4-/- mice are caused by 
effects on cancer stem cells, we first evaluated CSC numbers in MMTV-Wnt1 tumors.  
The limiting dilution transplantation assay has been used for a long time as a 
standard method for stem cell frequency calculation (Fazekas de St, 1982; Finney, 1951; 
Ploemacher, van der Sluijs, Voerman, & Brons, 1989). Here we used limiting dilution 
transplantation into nude mouse recipients to assess the CSC frequency in MMTV-Wnt1 
tumors, MDA-231 cell lines and wnt2508 cell lines which were generated and 
immortalized from a MMTV-Wnt1 mouse tumor.  
5 pairs of littermate MMTV-Wnt1 Lgr4+/+ and MMTV-Wnt1 Lgr4-/- mice with 
tumors were sacrificed when tumors reached 1.5cm at the greatest dimension. Tumors 
were excised and digested into single cell suspensions as described in Materials and 
Methods. The cell suspensions were injected orthotopically into 3-month old Nude 
mouse mammary gland with different cell numbers as indicated in Table 2. All mice 
were sacrificed when xenograft tumors reached 1.5 cm at greatest dimension or 3 
months after injection. The tumor outgrowths were recorded and the putative CSC 
numbers were calculated by a webtool extreme limiting dilution assay 
(http://bioinf.wehi.edu.au/software/elda/). 
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Figure 3 Deletion of Lgr4 delays tumor progression in MMTV-PyMT tumors 
Breast tissues or breast tumors from indicated ages and genotypes were collected for 
H&E staining, and histopathological analysis was used to evaluate tumor progression. At 
each time point analyzed, the extent of tumor progression was delayed in Lgr4-/- mice. 
Courtesy of Zengjin Yuan. 
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Figure 4 Lgr4 inactivation delays breast cancer progression in MMTV-Wnt1 tumors 
 A) Breast tissues or breast tumors from two-month old MMTV-Wnt1 mice were 
collected and subjected to H&E staining. The area of hyperplasia was compared between 
Lgr4+/+ and Lgr4-/-. B) Proliferating cells were detected by Ki67 immunohistochemistry 
in late stage (1.5 cm at greatest dimension) MMTV-Wnt1 tumors. C)  Bar graph showing 
quantitation of Ki67 positive cells ± S. E. per one hundred cells in MMTV-Wnt1 tumors, 
** p ≤ 0.01. 3 fields were counted for Ki67 positive cells in each mouse, and 3 mice 
were counted in both Lgr4+/+ and Lgr4-/- genotypes. 
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The data showed that the CSC frequency in MMTV-Wnt1 Lgr4+/+ tumors (1 CSC per 
2,758 cells) was 8 times higher than in MMTV-Wnt1 Lgr4-/- tumors (1 CSC per 21,963 
cells) (Table 2).  
The sphereculture assay first developed in neurogenesis research (Reynolds & 
Weiss, 1992) and later adopted for mammary gland study in which stem or progenitor 
cell populations can be enriched by sphereculture (Dontu, Al-Hajj, Abdallah, Clarke, & 
Wicha, 2003). Extensive studies showed that sphereculture can also enrich CSCs from 
several human breast cancer cell lines (Charafe-Jauffret et al., 2009; Fillmore & 
Kuperwasser, 2008). In order to assess the impact of Lgr4 ablation on the number of 
CSCs in MMTV-Wnt1 tumors, primary tumors from MMTV-Wnt1 Lgr4+/+ mice and 
MMTV-Wnt1 Lgr4-/- mice were digested, single tumor cell suspensions were made, and 
the in vitro tumorsphere assay was performed. As shown in Figure 5 A and B, the sphere 
formation was greatly reduced from 12 ± 3.6 spheres/10,000 cells in MMTV-Wnt1 
Lgr4+/+ tumors to 1.3 ± 1.15 spheres/10,000 cells in MMTV-Wnt1 Lgr4-/- tumors, 
suggesting a depletion of CSCs in MMTV-Wnt1 tumors by ablation of Lgr4 (Figure 5 A 
B).  
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Table 2 Limiting dilution assay in MMTV-Wnt1 tumors 
Lgr4+/+     Estimated CSC 
frequency 
cell number 102 103 104 105 1 in 2758 
Outgrowth 0/7 3/11 21/22 10/10 (1546-4919) 
Lgr4-/-      
cell number 102 103 104 105 1 in 21,963 
Outgrowth 0/8 1/12 11/22 9/10 (12,059-40,001) 
 
p=3.42e-07 
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Figure 5 Lgr4 inactivation leads to decreased sphere forming cell number in MMTV-
Wnt1 tumor 
A) MMTV-Wnt1 tumors under indicated genotypes were digested and cultured in 
tumorsphere medium as described. Pictures were taken at day 18 after seeding. 
Magnification: 200X. B) Bar graph showing number of sphere forming cells ± S. E. per 
10,000 cells in MMTV-Wnt1 tumors under indicated Lgr4 genotypes, N=3, * p≤0.05. 
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Table 3 Limiting dilution assay using serially passaged Wnt2508 cell line spheres 
2D culture     Estimated CSC frequency 
Cell number 50 500 5,000 50,000  
ShControl 1/3 2/3 3/3 3/3 1 in 334.8 (93.3 – 1,021) 
ShLgr4 0/3 0/3 3/3 3/3 1 in 11,786 (2,892 – 48,027) 
1st passage      
Cell number 50 500 5,000 50,000  
ShControl 0/3 3/3 3/3 3/3 1 in 208.6 (5.2 – 746.5) 
ShLgr4 0/3 1/3 3/3 3/3 1 in 1,170 (285 – 4,802) 
4th passage      
Cell number 50 100 500 1,000  
ShControl 1/3 0/3 3/3 3/3 1 in 219.9 (83.3 – 576.9) 
ShLgr4 0/3 1/3 1/3 2/3 1 in 859 (307 – 2402) 
7th passage      
Cell number 50 100 500 1,000  
ShControl 1/5 3/5 4/5 3/3 1 in 208.9 (97 – 454) 
ShLgr4 2/5 1/5 1/5 2/3 1 in 778 (327 – 1851) 
 
2D culture p=0.0105 
1st passage p=0.0225 
4st passage p=0.0552 
7st passage p=0.0166 
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Table 4 Limiting dilution assay using MDA-231 cell lines 
ShControl 
 
    Estimated CSC 
frequency 
cell number 103 104 105 106 1 in 45,903 
Outgrowths  / # 
injected mammary 
glands 
0/6 2/6 5/6 6/6 (18,996 – 110,925) 
ShLgr4      
cell number 103 104 105 106 1 in 569,691 
Outgrowths  / # 
injected mammary 
glands 
0/6 0/6 1/6 5/6 (235,901 – 1,375,781) 
 
p=9.8e-05 
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To confirm the result that Lgr4 inactivation led to decreased CSC frequency in 
MMTV-Wnt1 tumor, we also examined the effect of Lgr4 knockdown on CSCs in the 
mouse breast cancer cell line Wnt2508. We infected Wnt2508 cells with ShLgr4 or 
ShControl lentivirus. Serial sphereculture assay was adopted to enrich CSCs and then 
transplantation assays were performed using infected Wnt2508 cells grown in 2D 
culture, 1st passage sphere culture, 4th passage sphere culture, and 7th passage sphere 
culture to assess how Lgr4 knockdown affects CSC frequency and enrichment following 
serial sphereculture. An initial passage of sphere culture resulted in an increased CSC 
frequency from 1 in 335 (standard deviation was 93 to 1021) to 1 in 209 (standard 
deviation was 5.2 to 747) in ShControl, and from 1 in 11,786 (standard deviation was 
2892 to 48,027) to 1 in 1,170 (standard deviation was 285 to 4802). However, over 
several sphereculture passages, we noted a general increase in CSC frequency in both 
ShLgr4 and ShControl-infected cells. CSC frequency was significantly decreased after 
Lgr4 knockdown in every transplantation assay (Table 3). Therefore, our results from 
the limiting dilution tumorigenesis assay using MMTV-Wnt1 tumor or Wnt1 induced 
mouse mammary cancer cell line suggested Lgr4 affects CSC number in MMTV-Wnt1 
induced mammary cancer. 
We then tested if Lgr4 knockdown has a similar effect in human breast cancer 
cell lines. With a lentivirus containing an LGR4 targeting ShRNA (shLGR4) or a 
Nonsense control sequence produced as described in Materials and Methods, MDA-231 
cells were infected transiently with ShRNA lentivirus or ShContol lentivirus (efficiency 
shown in Figure 6). Varying dilutions of cells were injected into the mammary glands of 
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2-month old Nude mice. The numbers of cells injected and recipients are indicated in 
Table 4. The numbers of tumor outgrowths were recorded and putative CSC numbers 
were calculated by ELDA. Lgr4 knockdown led to a 92% decrease in CSC frequency in 
MDA-231 cells (Table 4).  
Sox genes encode a family of transcription factors which play important roles in 
development by affecting stem cells (Sarkar & Hochedlinger, 2013). Nanog, Oct4 and 
Sox2 were reported be to key genetic regulators in human embryonic stem cells (Rodda 
et al., 2005). Further studies showed that Sox2 fosters various cancers by promoting 
cellular proliferation, evading apoptosis, and enhancing invasion and migration (Weina 
& Utikal, 2014). And two papers reported Sox2 to be a CSC marker in breast cancer 
(Leis et al., 2012) and squamous cell carcinoma (Boumahdi et al., 2014). We have 
previously reported a decrease in Sox2 expression of mammospheres cultured from 
primary mammary cells of Lgr4-/- mice as compared to those from Lgr4+/+ mice (Y. 
Wang et al., 2013). We therefore examined whether Sox2 levels are affected by loss of 
Lgr4. Indeed, Sox2 mRNA expression levels were significantly decreased in MMTV-
Wnt1 Lgr4-/- tumors when compared with MMTV-Wnt1 Lgr4+/+ tumors (Figure 6 A), 
and Sox2 positive cells indicated by immunohistochemistry also demonstrated a 
dramatic decrease from 10.2% ± 1.43% in MMTV-Wnt1 Lgr4+/+ tumors to 5.7% ± 
1.41% in MMTV-Wnt1 Lgr4-/- tumors (Figure 6 B&C). Similar results were observed as 
a result of LGR4 knockdown in MDA-231 cells and Wnt2508 cells (Figure 6 D&E), 
suggesting that Sox2 is regulated by Lgr4 in MMTV-Wnt1 induced mammary cancer 
and MDA-231 cells. We next examined whether MMTV-Wnt1 tumor cells that express 
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Lgr4 are also Sox2+. We performed immunohistochemistry for Sox2 in -gal stained 
MMTV-Wnt1 Lgr4+/- tumors. Notably Sox2 does not co-localize with Lgr4 in MMTV-
Wnt1 tumors (data not shown), suggesting that a paracrine signaling pathway regulated 
by Lgr4 is involved in control of Sox2 expression in MMTV-Wnt1 tumors.   
 
III.4 Lgr4 inactivation results in decreased metastasis by affecting EMT 
As the final and the most fatal step of tumor progression, metastasis is associated 
with pain, distant metastasized organ malfunction and lethality. In order to form a 
metastasis at distant organ, the metastatic cells from the primary tumor must undergo 
several steps: (1) intravasation from primary tumor site; (2) survival and dissemination 
in the circulation; (3) extravasation; (4) colonization in distant organs and generation of 
metastases (Klein, 2008). Loss of Lgr4 has been reported to cause diminished 
invasiveness in several cancer cell lines as well as in colon cancer (Gao, Kitagawa, 
Hiramatsu, et al., 2006; J. Wu et al., 2013). 
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 Figure 6 Ablation of Lgr4 represses Sox2 expression in breast cancers 
A) Bar graph showing relative mRNA level in MMTV-Wnt1 tumors under indicated 
genotypes. B) Sox2 expression (brown) in MMTV-Wnt1 tumors under indicated 
genotypes are shown by immunohistochemistry. C) Bar graph showing % of cells 
expressing Sox2 (Sox2 positive cell percentage) in MMTV-Wnt1 tumors under indicated 
Lgr4 genotypes. Bar graph showing the mean Sox2+ cell percentage ± S. E., * p≤0.05. D 
& E) Bar graph showing Sox2 relative mRNA level ± S. E in MDA-231 (D) and 
Wnt2508 cells (E), **p≤0.01, ***p≤0.001.  
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III.4.1 Breast cancer metastasis to lungs is repressed by Lgr4 depletion in MMTV-Wnt1 
and MMTV-PyMT mice  
A previous report showed that Lgr4 knockdown blocks invasion in several cancer 
cell lines (Gao, Kitagawa, Hiramatsu, et al., 2006). To explore whether Lgr4 has the 
same function in breast cancer, we first evaluated the lung metastasis in MMTV-Wnt1 
and MMTV-PyMT mice bearing mammary tumors measuring 1.5 cm at the greatest 
dimension. By H&E staining, the pathological analysis showed that MMTV-PyMT 
Lgr4+/- mice had a dramatic reduction in metastasis formation when compared with 
MMTV-PyMT Lgr4+/+ (Figure 7 A). The number of metastases per field dropped from 
an average of 19 in Lgr4+/+ to 4 in Lgr4+/- (Figure 7 B). Although no significant 
difference was detected in the MMTV-Wnt1 mice due to low sample size, only MMTV-
Wnt1 Lgr4+/+ developed metastasis in the lung (3 out of 8) and no metastases were 
detected in MMTV-Wnt1 Lgr4-/- mice (0 out 6) (data not shown). By using QPCR, Lgr4 
mRNA levels in 6 different breast cancer cell lines were measured. As shown in Figure 1 
B, the three most invasive breast cancer cell lines have the highest Lgr4 expression, 
which suggests a strong correlation between Lgr4 mRNA level and breast cancer 
invasiveness. Therefore, these data strongly suggested that Lgr4 expression is positively 
related with breast cancer metastasis. 
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III.4.2 Lgr4 knockdown in MDA-231 cells results in decreased cell migration and 
attenuated lung metastasis formation  
To better demonstrate Lgr4 function in metastasis, we then examined the effect 
of Lgr4 knockdown on migration in vitro. In the the trans-well migration assay, Lgr4 
knockdown significantly inhibited cell migration of MDA-231, MDA-468 and Hs578T 
cells (Figure 8 A&B). The inhibition of migration by inactivation of LGR4 was then 
confirmed in MDA-231 wound healing assay (Figure 8 C&D).  
We next sought to determine whether Lgr4 knockdown MDA-231 cells were 
impaired in metastasis formation. We injected luciferase-expressing MDA-231 cells also 
stably expressing either shLGR4 or shNC (a non-specific control shRNA) into the tail 
vein of nude mice. LGR4 knockdown resulted in significantly decreased luciferase 
activity detected in the lungs 30 days after injection when compared with ShControl 
(Figure 9), suggesting that the metastasis formation abilities of MDA-231 cells are 
heavily impaired by knocking down Lgr4. 
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Figure 7 Lgr4 deletion leads to inhibition of lung metastasis formation in MMTV-PyMT 
mice 
A) Hematoxylin & Eosin staining showing lung metastasis under indicated genotypes. 
B) Graph showing number of metastatic foci ± S.E. per mouse under indicated 
genotypes, *p≤0.05. 
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Figure 8 Lgr4 expression level positively correlates with in vitro migration ability in 
human breast cancer cell lines 
A) Trans-well assay using MDA-231, MDA-468 and Hs578T cells infected with 
indicated ShRNA containing lentivirus; migrating cells are indicated with Crystal Violet 
staining. B) Bar graph showing relative percentage ± S.E. of control migrated cells in 
transwell assay. ***p<0.001. C) Wound healing assay using MDA-231 cells infected 
with indicated ShRNA containing lentivirus. Wound edges are indicated with white 
dashed lines. D) Bar graph showing number of migrated cells ± S.E. **p<0.01. A-B 
Courtesy of Yuanzhang Fang. 
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Figure 9 Inactivation of LGR4 inhibits in vivo lung metastasis formation in MDA-231 
cell line 
A) The lung bioluminescence photon values on days 0, 20, and 30 in ShControl and 
ShLGR4 MDA-231 tailvein injection assay. B) Bar graph showing luciferase activity ± 
S.E. in lung on day 30. **p<0.01. C) Lung metastasis comparison between ShControl 
and ShLgr4 MDA-231 tailvein injection on day 30. White spots indicate macroscopic 
lung metastases. D) Hematoxylin & Eosin staining of lung tissues from indicated tailvein 
injection group; black arrows indicate metastases. Courtesy of Zhiying Yue. 
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III.4.3 Breast cancer EMT is blocked by inactivation of Lgr4 
Recently published reports revealed that EMT is closely associated with CSCs, 
and plays important roles in cancer invasion and metastasis (Mani et al., 2008; Scheel & 
Weinberg, 2012). Since ablation of Lgr4 decreased CSC number as well as metastasis, 
we suspected that Lgr4 positively regulates EMT, resulting in promotion of invasion and 
migration. In order to test this hypothesis, we first performed the in vitro 3D colony 
formation assay (Debnath, Muthuswamy, & Brugge, 2003) using MCF10A cells stably 
expressing both ErbB2 and 14-3-3ξ (MCF10A-ErbB2-14-3-3ξ), which is a viable model 
for EMT studies (Lu et al., 2009). By measuring the length and number of branches 
invading into the surrounding Matrigel from the acinar structured colonies of MCF10A-
ErbB2-14-3-3ξ cells, we can evaluate the invasiveness. Strikingly, the invasive branches 
in LGR4 wild-type MCF10A colonies were greatly decreased by LGR4 knockdown 
(Figure 10 A). We examined the effect of LGR4 knockdown on colony expression of 
EMT markers. mRNA analysis of selected EMT markers showed decreased expression 
of N-cadherin, SNAL1, SNAL2 and increased E-cadherin after LGR4 knockdown, 
which supported a reversal of EMT in cells expressing shLGR4 (Figure 10 B). We then 
examined EMT marker expression in MMTV-Wnt1 mammary tumors. mRNA levels of 
both Snail and Slug were decreased in tumors from Lgr4-/- mice, whereas E-cadherin 
mRNA was elevated in tumors lacking Lgr4, supporting an essential role for Lgr4 in 
tumor EMT. We also observed a dramatically increased E-cadherin protein expression in 
MMTV-Wnt1 Lgr4-/- tumors compared to MMTV-Wnt1 Lgr4+/+ tumors (Figure 10 
C&D). Taken together our data suggests that Lgr4 promotes metastasis through EMT.  
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Figure 10 Lgr4 affects EMT genes in ErbB2 and 14-3-3ζ transformed MCF-10A 3D 
organoids and MMTV-Wnt1 tumors 
A) Representative 3D culture organoids from plating 1000 cells/well of ErbB2 and 14-3-
3ζ transformed MCF-10A cells infected with indicated ShRNA containing virus. Length 
and number of invading branches in surrounding Matrigel from the acinar structure were 
measured for invasive potential evaluation. B) Bar graph showing relative mRNA level 
± S.E of indicated genes in ErbB2 and 14-3-3ζ transformed MCF-10A 3D organoids, 
*p≤0.05. C) Bar graph showing relative mRNA level ± S.E of indicated genes in 
MMTV-Wnt1 tumors under indicated Lgr4 genotypes, *p≤0.05, **p≤0.001, 
***p≤0.0001. D) E-cadherin expression (brown) in MMTV-Wnt1 tumors under 
indicated genotypes is shown by immunohistochemistry. A-B courtesy of Ying Wang. 
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III.5 Lgr4 modulates Wnt pathway, EGFR pathway, and MMPs in breast cancers 
The Wnt signaling pathway is a key regulator in cancer progression (Anastas & 
Moon, 2013), cancer stem cells (Holland, Klaus, Garratt, & Birchmeier, 2013) and EMT 
(Y. Wu et al., 2012), and our previous study showed that Lgr4 regulates Sox2 expression 
level in mammary gland development through wnt signaling (Y. Wang et al., 2013). In 
order to investigate whether the Wnt pathway mediates Lgr4 regulated breast cancer 
progression, wnt target gene mRNA levels were measured in MMTV-Wnt1 tumors 
under Lgr4+/+ and Lgr4-/- genotypes. Quantitative  PCR showed that the mRNA level of 
wnt1, wnt3a, wnt4, Nanog and TCF1 are significantly decreased in MMTV-Wnt1 Lgr4-/- 
tumors compared with MMTV-Wnt1 Lgr4+/+ tumors (Figure 11 A). Furthermore, the 
TOP-Flash assay in MDA-231 cells also showed decreased the Wnt signaling pathway 
reporter activity in MDA-231, MDA-468 and Hs578T human breast cancer cell lines 
after knockdown of LGR4 (Figure 11 B). Furthermore, Western blot analysis showed a 
decreased level of the active form of β-catenin in these three cell lines after Lgr4 
inactivation (Figure 11 C).  
Epidermal growth factor receptor (EGFR) pathway is a downstream target of the 
canonical Wnt pathway (Schlange, Matsuda, Lienhard, Huber, & Hynes, 2007), and also 
actively participates in cancer progression (Masuda et al., 2012) and as well as in EMT 
(Lo et al., 2007). In order to explore whether the EGFR pathway is affected by Lgr4 in 
breast cancer, we checked the level of phosphoY1068-EGFR, a marker of EGFR 
activity, in MDA-231 cells after LGR4 knockdown. The Western blot showed a 
decreased level of phosphorylatedY1068 EGFR after LGR4 knockdown, and DKK 
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treatment showed no significant difference in terms of pY1068-EGFR level, suggesting 
that the EGFR pathway in MDA-231 cells is regulated at least in part through Wnt-
independent mechanisms (Figure 11 D). Matrix metalloproteinases (MMPs) are a family 
of zinc-dependent endopeptidases which are known to play important roles in tumor cell 
invasion and survival. Among them, the active form of MMP9 has been shown be able 
to activate EGFR and disrupt E-cadherin expression in ovarian cancer (Cowden Dahl et 
al., 2008). Here, our quantitative PCR results also demonstrated MMP9 and MMP13 
mRNA level are consistently decreased in MDA-231 and MMTV-Wnt1 tumors after 
inactivation of Lgr4 (Figure 11 E&F). Taken together, our results suggested Lgr4 is a 
master regulator of breast cancer.  
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Figure 11 Lgr4 is a master regulator of breast cancer by modulating Wnt pathway, 
EGFR pathway and MMPs 
A) Bar graph showing relative mRNA level ± S.E of indicated wnt target genes *p≤0.05, 
**p≤0.01, ***p≤0.001. B) Bar graph showing Top luciferase activity ± S.E in indicated 
cell lines with indicated ShRNA. C) Western blot showing expression level of active β-
catenin level (clone 8E7) in indicated cell lines. D) Western blot showing pEGFR level 
with or without treatment of DKK-1. E) Bar graph showing relative mRNA level ± S.E 
of indicated MMPs in MDA-231. F) Bar graph showing relative mRNA level ± S.E of 
indicated MMPs in MMTV-Wnt1 tumors, *p≤0.05. B-E courtesy of Yuanzhang Fang.
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CHAPTER IV 
DISCUSION 
 
IV.1 Overview 
Our lab has been focused on the function of Lgr4 in development of various 
organs for a long time. This study, as well as another prostate cancer study conducted by 
Weijia Luo, was the first time we investigated the link between Lgr4 and cancer. The 
first clue leading us to this study is a paper published on 2006 that Lgr4 promotes 
invasiveness and metastasis in several carcinoma cell lines (Gao, Kitagawa, Hiramatsu, 
et al., 2006). And our first evidence of Lgr4 cancer-related phenomenon was finding that 
the tumor growth in Lgr4-null MMTV-PyMT mice is significantly delayed when 
compared with tumor growth in Lgr4 wild-type MMTV-PyMT mice. Combined with an 
earlier publication and our data-base-analysis that Lgr4 expression level is correlated 
with migration ability in several breast cancer cell lines and breast cancer recurrence in 
human patients (Gao, Kitagawa, Hiramatsu, et al., 2006), we suspected that Lgr4 may 
affect breast cancer progression and metastasis as well. Subsequent studies gave data 
that supported our hypothesis, and even more striking findings: loss of Lgr4 heavily 
impairs metastasis to lungs in MMTV-PyMT mice and MDA-231 tail vein injection 
assay. At that time, several labs reported that LGR4 potentiates the Wnt signaling upon 
binding of RSPOs (W. B. de Lau et al., 2012), and Wnt signaling pathway had been 
shown to regulate stem cell and CSC activities (Holland et al., 2013). Then our lab 
published two papers which reported Lgr4 to be a stem cell regulator through Wnt 
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pathway in both the prostate and mammary gland; and notably Sox2 is directly regulated 
by Lgr4 in mammary gland stem cells (W. Luo et al., 2013; Y. Wang et al., 2013). Sox2 
was then reported as a CSC marker for breast cancer and squamous (Boumahdi et al., 
2014; Leis et al., 2012). All these studies supported a link between Lgr4 and breast 
CSCs. Since Lgr4 is mainly expressed in mammary gland basal cells, we crossed our 
Lgr4 knockout mice with MMTV-Wnt1 mice which is a popular basal-originated breast 
cancer model (Y. Li et al., 2000). In MMTV-Wnt1 mice, tumor progression is repressed 
as well. We aimed to evaluate the CSC numbers in MMTV-Wnt1 tumors with different 
Lgr4 genotypes. Therefore we performed transplantation assay and in vitro sphereculture 
assay which both showed decreased CSC frequency in Lgr4 low groups. Furthermore, 
Lgr4 knockdown in MDA-231 showed a similar outcome in Xenograft assay and 
tumorsphere assay. All these results revealed a strong correlation between reduction in 
Lgr4 level and decreased CSC frequency. On the other hand, we aimed to explore 
whether Lgr4 affected metastasis through EMT which is one hallmark of CSCs (Mani et 
al., 2008). To assess the role which Lgr4 plays in migration and invasion, we adopted 
trans-well assay and in vitro 3D culture assay. Lgr4 knockdown in all breast cancer cell 
lines we tested showed decreased motilities which supported our earlier observation of 
metastasis abrogation in MMTV-PyMT Lgr4-/- mice. 
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IV.2 Significance 
Our findings generate new insight into LGR4 in breast cancer and the overall 
understanding of GPCRs. More specifically, our results for the first time showed that 
LGR4 is a key regulator of breast cancer stem cells. Furthermore, our results also 
showed that LGR4 regulates breast cancer progression in different ways: 1. LGR4 
affects breast cancer frequency 2. LGR4 affects metastasis 3. LGR4 affects cancer cell 
EMT. Finally, our signaling experiments in breast cancer showed that LGR4 affects the 
Wnt pathway, EGFR pathway and several MMP proteins level as well. Thus we 
provided a potential therapeutic target for breast cancer treatment. By targeting LGR4, 
we may be able to inhibit several cancer promoting pathways, reduce tumor promotion 
and block distant metastasis.  
 
IV.3 Limitations 
Lack of human breast cancer data. All our experiments were performed using cell 
lines and breast cancer mouse models. Although these experiments covered both in vivo 
and in vitro conditions, a human patient based experiment which confirms our results in 
mouse and cell lines would be essential to support the clinical validity of our findings. 
Lack of effective methods to isolate genuine cancer stem cells. Although our 
results suggested that we enriched cancer stem cells up to 1 in 220 cancer cells in serial 
sphereculture and transplantation assay, we still cannot exclude the possibility that those 
220 cancer cells work as a group to generate a xenograft tumor. In addition we could not 
sort out viable CD24+/CD90+ cells from MMTV-Wnt1 tumors. Possibly due to technical 
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difficulties, we cannot reproduce the data in two previous papers (R. W. Cho et al., 
2008; Malanchi et al., 2012). The development of more definitive CSC separation 
protocols would allow an evaluation of Lgr4 function in breast CSCs in greater depth. 
 
IV.4 Future directions  
One of our future directions will be focused on how Lgr4 functions in EMT 
regulation in vivo. Our results have shown EMT gene expression are affected by Lgr4 
inactivation, but we have not yet demonstrated direct evidence that Lgr4 affects EMT in 
vivo. To achieve this, we will isolate circulating tumor cells from MDA-231 xenograft 
recipient blood by using GFP, and then analyze the EMT markers altered in those cells 
expressing either shNC or shLGR4. This experiment will give us direct evidence of 
LGR4 regulating EMT in vivo. Furthermore, we have shown that the EGFR and Wnt 
pathways are affected by Lgr4 in breast cancer, but we have not yet answered whether 
the GPCR canonical cAMP/CREB pathway also participates in Lgr4-mediated cancer 
regulation. To answer these questions, Lgr4-T775I, a mutated Lgr4 construct which 
constitutively activates the cAMP/CREB pathway, will be used in this study. With wnt 
antagonist or EGFR antagonist controls, we will be able to study the impact of each 
pathway on EMT and cancer progression. 
Another future direction will be to study the role of LGR4 in drug resistance. Our 
previous data has shown that loss of LGR4 impairs resistance of MDA-231 and MCF7 
against the breast cancer drugs doxorubicin and docetaxel. 
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CHAPTER V 
CONCLUSIONS 
 
Group B LGRs have been shown as stem cell markers in proliferative tissues 
such as the intestines and hair follicles. Lgr4 participates in the development of multiple 
organs, and recently Lgr4 has been reported as a stem cell regulator in the mammary 
gland and prostate. Two papers reported that Lgr4 promotes invasion or metastasis in 
several cancer cell lines and colorectal cancer, one paper reported that LGR4 non-sense 
mutation in human patients is related with several diseases and cancers, but the overall 
mechanism how Lgr4 affects cancer is still largely unknown. This is the first 
investigation that focused on LGR function in breast cancer stem cells. In this study, we 
report that Lgr4 inactivation in the MMTV-Wnt1 mouse model decreased the number 
and tumorigenic ability of CSCs. Metastasis, the final and the most fatal step of cancer, 
is always a priority in breast cancer treatment. Especially in those patients who 
developed TNBC, finding a method to delay metastasis formation is very challenging. 
Here, our results from several TNBC cell lines studies revealed that LGR4 affects 
multiple signaling pathways. By knocking down LGR4 in these TNBC cell lines, 
metastasis was attenuated. Last but not least, we found that Lgr4 positively regulated the 
Wnt signaling pathway, EGFR pathway and MMPs in breast cancer. Taken together, this 
study is the first investigation on LGR4 function in breast cancer stem cells which may 
help future clinical strategies against breast cancer progression and metastasis. 
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